<SEC-DOCUMENT>0001193125-24-197821.txt : 20240809
<SEC-HEADER>0001193125-24-197821.hdr.sgml : 20240809
<ACCEPTANCE-DATETIME>20240809160537
ACCESSION NUMBER:		0001193125-24-197821
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240808
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240809
DATE AS OF CHANGE:		20240809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Axogen, Inc.
		CENTRAL INDEX KEY:			0000805928
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				411301878
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36046
		FILM NUMBER:		241192569

	BUSINESS ADDRESS:	
		STREET 1:		13631 PROGRESS BLVD.
		STREET 2:		SUITE 400
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615
		BUSINESS PHONE:		(386) 462-6817

	MAIL ADDRESS:	
		STREET 1:		13631 PROGRESS BLVD.
		STREET 2:		SUITE 400
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AxoGen, Inc.
		DATE OF NAME CHANGE:	20111004

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LECTEC CORP /MN/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d831362d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:axgn="http://www.axogeninc.com/20240808" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-319">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-08-08_to_2024-08-08">0000805928</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="axgn-20240808.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-08-08_to_2024-08-08"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-08</xbrli:startDate> <xbrli:endDate>2024-08-08</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-330">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Report</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-08-08_to_2024-08-08" format="ixt:datemonthdayyearen" id="ixv-331">August&#160;8, 2024</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-332">AXOGEN, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-08-08_to_2024-08-08" format="ixt-sec:stateprovnameen" id="ixv-333">Minnesota</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-334">001-36046</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-335">41-1301878</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation or Organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-336">13631 Progress Boulevard</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-337">Suite 400</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-338">Alachua</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-08-08_to_2024-08-08" format="ixt-sec:stateprovnameen" id="ixv-339">Florida</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-340">32615</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-341">(386)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-342">462-6800</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-08-08_to_2024-08-08" format="ixt-sec:boolballotbox" id="ixv-343">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-08-08_to_2024-08-08" format="ixt-sec:boolballotbox" id="ixv-344">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-08-08_to_2024-08-08" format="ixt-sec:boolballotbox" id="ixv-345">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-08-08_to_2024-08-08" format="ixt-sec:boolballotbox" id="ixv-346">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-</span> 4(c))</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-347">Common Stock, $0.01 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-348">AXGN</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-08-08_to_2024-08-08" format="ixt-sec:exchnameen" id="ixv-349">The Nasdaq Stock Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-08-08_to_2024-08-08" format="ixt-sec:boolballotbox" id="ixv-350">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Directors. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Appointment of Michael Dale as Chief Executive Officer, President, and Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;8, 2024, Axogen, Inc. (the &#8220;Company&#8221;), announced the appointment of Michael Dale as its Chief Executive Officer (&#8220;CEO&#8221;) and President, effective August&#160;9, 2024 (the &#8220;Effective Date&#8221;). The Company also announced that Mr.&#160;Dale was appointed as a member of the Board as of the Effective Date. In connection with Mr.&#160;Dale&#8217;s appointment as the Company&#8217;s CEO and President, the Company entered into an employment agreement with Mr.&#160;Dale effective August&#160;9, 2024 (the &#8220;Employment Agreement&#8221;). As a material inducement of employment, Mr.&#160;Dale was granted 600,000 performance stock units (&#8220;PSUs&#8221;). Shares representing 450,000 PSUs will vest according to performance metrics tied to the achievement of Company stock price goals between February&#160;22, 2024 and ending February&#160;22, 2027 (&#8220;TSR PSUs&#8221;). Mr.&#160;Dale will earn from 0% to 200% of the TSR PSUs upon achievement of specific Company stock price goals. Shares representing 150,000 PSUs will fully vest upon approval of the Company&#8217;s biologics license application for Avance Nerve Graft during the performance period beginning from January&#160;1, 2024 and ending December&#160;31, 2025. Pursuant to the Employment Agreement, Mr.&#160;Dale&#8217;s annual base salary is $765,000 and he is eligible to participate in the Company&#8217;s bonus plan with the target bonus being 100% of his annual base salary. Pursuant to the Employment Agreement, upon Mr.&#160;Dale&#8217;s termination without Substantial Cause (as defined in the Employment Agreement) or for Good Reason (as defined in the Employment Agreement) (either a &#8220;Qualifying Termination&#8221;) Mr.&#160;Dale will be eligible to receive severance benefits, including continuation of salary, bonus payments, and COBRA payments per the Employment Agreement that are materially consistent with those offered to the Company&#8217;s other senior executives. Upon Mr.&#160;Dale&#8217;s Qualifying Termination during the <span style="white-space:nowrap">one-year</span> following a Change in Control (as defined in the Employment Agreement), Mr.&#160;Dale will be eligible to receive enhanced severance benefits, including continuation of salary, bonus payments, and COBRA payments, and also accelerated vesting of any then-unvested time-vesting restricted stock units or stock options, and a <span style="white-space:nowrap">one-year</span> post-termination exercise period for any outstanding stock options. The foregoing description of the Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Employment Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated by reference here. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Dale, 65, has over 30 years of industry experience leading transformative, high-technology medical device companies in the cardiovascular, neuromodulation, diabetes, and electrophysiology markets. From March 2016 to January 2024, Mr.&#160;Dale served as a Senior Vice President and Corporate Officer and President of the structural heart business at Abbott (NYSE: ABT). From September 2014 to March 2016, he served as the President and Chief Executive Officer of Morphic Medical (f/k/a GI Dynamics). Mr.&#160;Dale also held past executive leadership roles at Helical Solutions, ATS Medical, Endocardial Solutions, Cyberonics, St. Jude Medical, and Edwards Life Sciences. Mr.&#160;Dale currently serves on the advisory board of Purdue University&#8217;s Weldon School of Biomedical Engineering, and the University of Minnesota Carlson School of Management Medical Industry Leadership Institute, and also serves as a Student Mentor for the California Polytechnic State University&#8217;s Center for Innovation&#160;&amp; Entrepreneurship. From December 2011 to March 2016, Mr.&#160;Dale served as the Chairman of the Board of Directors of Preceptis Medical, Inc and from March 2014 to April 2016, he served on the Board of Directors of NeoChord, Inc. Mr.&#160;Dale has also served as on the board of directors of Neuronetics, Inc., Enpath Medical, Rythmia Medical, the Advanced Medical Technology Association, and St. Mary&#8217;s University Council of Regents for the School of Graduate and Professional Programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Dale holds a Bachelor of Science degree from California Polytechnic State University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&#160;Dale does not have any family relationships with any director or executive officer of the Company, and there are no arrangements or understandings with any persons pursuant to which Mr.&#160;Dale has been appointed to his position. In addition, there have been no transactions directly or indirectly involving Mr.&#160;Dale that would be required to be disclosed pursuant to Item 404(a) of Regulation <span style="white-space:nowrap">S-K</span> under the Securities Exchange Act of 1934, as amended. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Appointment of Paul G. Thomas as Chair of the Board </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of the Effective Date, Paul G. Thomas was appointed to serve as Chair of the Board. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Retirement of Karen Zaderej as Chief Executive Officer and Member of the Company&#8217;s Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of that certain Transition and Separation Agreement, dated January&#160;4, 2024, as of August&#160;8, 2024, Karen Zaderej stepped down as the Company&#8217;s CEO and Board duties. As previously disclosed in the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the Securities and Exchange Commission on January&#160;4, 2024, Ms.&#160;Zaderej will continue to provide services as an employee of the Company for nine months following the Effective Date. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;8, 2024, the Company issued a press release announcing the appointment of Mr.&#160;Dale as the Company&#8217;s Chief Executive Officer and the appointment of Mr.&#160;Thomas as Chair of the Board. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 7.01 including 99.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or Exchange Act, except as shall be expressly set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d831362dex101.htm">Employment Agreement, dated August&#160;9, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d831362dex102.htm">Axogen, Inc. Performance-Based Restricted Stock Units Notice Inducement Award Agreement, effective as of August&#160;9, 2024, by and between the Company and Michael Dale (TSR) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.3*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d831362dex103.htm">Axogen, Inc. Performance-Based Restricted Stock Units Notice Inducement Award Agreement, effective as of August&#160;9, 2024, by and between the Company and Michael Dale (Performance) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d831362dex991.htm">Axogen Inc. Press Release, dated August&#160;8, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Management contract or compensatory plan arrangement. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">AXOGEN, INC.</td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Dated: August&#160;9, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Began</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Marc Began</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President, General Counsel and Chief<br/>Compliance Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d831362dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution Version </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXECUTIVE EMPLOYMENT AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS EXECUTIVE EMPLOYMENT AGREEMENT</B> (the &#147;Agreement&#148;), effective as of August&nbsp;9, 2024 (the &#147;Effective Date&#148;), is made by and
between AXOGEN CORPORATION, a Delaware corporation (&#147;AXOGEN&#148;), and Michael Dale (&#147;Executive&#148;) (collectively, the &#147;Parties&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, AXOGEN and the
Executive desire to enter into this Agreement to state the terms and conditions of the Agreement in its entirety on the Effective Date on the terms and conditions set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the promises set forth in this Agreement, and for other good and valuable consideration, the receipt and adequacy
of which is acknowledged by this Agreement, the Parties to this Agreement, intending to be legally bound, agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Employment</U>.
AXOGEN hereby employs Executive, and Executive hereby accepts such employment, all upon the terms and conditions set forth in this Agreement, including those set forth in the attached Schedules and Exhibits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Duties of Executive</U>. The duties of Executive, as may be amended from time to time, are set forth on Schedule 1 of this
Agreement, which is attached hereto and incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Compensation and Benefits</U>. The compensation
and benefits to which Executive may be entitled pursuant to this Agreement are set forth on Schedule 2 of this Agreement, which is attached hereto and incorporated herein by reference. All payments and benefits provided by AXOGEN to Executive
pursuant to this Agreement and Schedule 2 shall be subject to recoupment in accordance with any claw-back policy of AXOGEN adopted pursuant to the listing standards of any national securities exchange or association on which AXOGEN&#146;s securities
are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Confidentiality, Intellectual Property, <FONT STYLE="white-space:nowrap">Non-Competition</FONT> and
<FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement</U>. Contemporaneously with the execution and delivery of this Agreement, Executive shall enter into a Confidentiality, Intellectual Property,
<FONT STYLE="white-space:nowrap">Non-Competition</FONT> and <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement (the &#147;Confidentiality Agreement&#148;) attached hereto as <U>Exhibit A</U> to this Agreement, which shall be
incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. &#8195;<U>Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U><FONT STYLE="white-space:nowrap">At-will</FONT></U>. Either AXOGEN or Executive may terminate this Agreement at any time during
the course of Executive&#146;s employment and for any reason, upon giving written notice to the other party. Other than as described in this Agreement, AXOGEN shall have no further liability or obligation to Executive other than to pay for services
rendered through Executive&#146;s last date of employment. If Executive elects to terminate this Agreement and provides AXOGEN with any notice period prior to the date of termination, AXOGEN may elect to terminate this Agreement immediately thereon
and incur no further obligation to Employee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">other than for wages worked through the date of termination of this Agreement and any
other remuneration expressly set forth herein or as otherwise set forth in AXOGEN&#146;s policies. It is the intention of the Parties that at all times this shall be an <FONT STYLE="white-space:nowrap">at-will</FONT> employment relationship during
the course of Executive&#146;s employment with AXOGEN. Nothing contained in this Agreement shall be deemed or construed to create a contractual relationship between the Parties for a specific duration of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Death</U>. In the event of the death of the Executive, this Agreement shall terminate on the date of Executive&#146;s death,
without any liability to or upon AXOGEN other than to pay for services rendered prior to the date of the Executive&#146;s death, subject to the terms of AXOGEN&#146;s plans and policies, as may be amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Permanent Disability</U>. For purposes of this Agreement, the term &#147;Permanent Disability&#148; shall mean a physical or
mental incapacity of Executive as determined by an independent medical examination, which renders Executive unable to perform Executive&#146;s duties pursuant to this Agreement, and which shall continue for ninety (90)&nbsp;consecutive days or one
hundred and eighty (180)&nbsp;days during any twelve-month period. If AXOGEN or Executive terminates Executive&#146;s employment by reason of Permanent Disability of Executive, this Agreement shall terminate immediately upon written notice by AXOGEN
to Executive, or the date Executive gives notice to terminate employment to AXOGEN, without any liability to or upon AXOGEN other than to pay for services rendered through the termination date, subject to the terms of AXOGEN&#146;s plans and
policies, as may be amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Termination Payments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Definition</U>. For the purposes of this Agreement, a &#147;Change in Control&#148; shall mean the occurrence of any of the
following events: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i)&#8195;any &#147;person&#148; (as that term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of
1934, as amended (&#147;Exchange Act&#148;)), who holds less than twenty percent (20%) of the combined voting power of the securities of AXOGEN or its parent company Axogen, Inc. (&#147;INC.&#148;), becomes the &#147;beneficial owner&#146;&#146; (as
defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, of securities of AXOGEN or INC. representing fifty percent (50%) or more of the combined voting power of the securities of either AXOGEN
or INC. then outstanding; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;during any period of twenty-four (24)&nbsp;consecutive months, individuals, who, at the beginning
of such period constitute all members of the Board of Directors of INC. (the &#147;Board&#148;) and cease, for any reason, to constitute at least a majority of the Board, unless the election of each director who was not a director at the beginning
of the period was either nominated for election by, or approved by a vote of, at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the directors then still in office who were directors at the beginning of the period; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;AXOGEN or INC. consolidates or merges with another company, and AXOGEN or INC. is not the continuing or surviving corporation,
provided, however, that any consolidation or merger whereby INC. continues as the majority holder of AXOGEN securities or a merger or consolidation of AXOGEN and INC. will not constitute a Change in Control; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;shares of AXOGEN&#146;s or INC.&#146;s common stock are
converted into cash, securities, or other property, other than by a merger of AXOGEN or INC., pursuant to Section&nbsp;4(a)(iii), in which the holders of AXOGEN&#146;s or INC.&#146;s common stock immediately prior to the merger have the same
proportionate ownership of common stock of the surviving corporation as immediately after the merger; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(v)&#8195;AXOGEN or INC. sells,
leases, exchanges, or otherwise transfers all, or substantially all, of its assets (in one transaction or in a series of related transactions), provided, however, that any such transaction related to AXOGEN whereby INC. continues as the majority
holder of AXOGEN securities or INC. is the sole other party to the transaction, will not constitute a Change in Control; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(vi)&#8195;the
holders of AXOGEN&#146;s or INC.&#146;s stock approve a plan or proposal for the liquidation or dissolution of AXOGEN or INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Separation</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<U>Termination in Connection with a Change in Control</U>. In the event of Executive&#146;s termination of employment without
Substantial Cause (as defined below) or by Executive for Good Reason during the Protection Period, Executive will be entitled to a separation payment consisting of: (A)&nbsp;twenty-four (24)&nbsp;months of Executive&#146;s base salary; (B) 200% of
Employee&#146;s target bonus for the year in which the termination occurs; (C)&nbsp;accelerated vesting of any unvested AXOGEN time-vesting restricted stock units (&#147;RSUs&#148;) and time-vesting options to purchase shares of AXOGEN common stock
(&#147;Options&#148;) held by Executive and outstanding as of such termination, which such RSUs and Options shall accelerate and vest as of Executive&#146;s termination of employment; and (D)&nbsp;Executive shall have a period of <FONT
STYLE="white-space:nowrap">one-year</FONT> from the date of such termination to exercise any vested Options held by Executive at the time of such termination, including those Options that accelerate and vest in connection with such termination;
provided, however, in no event shall any Options be exercisable after the Expiration Date set out in the applicable award agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;For purposes of this Agreement, &#147;Protection Period&#148; means the period commencing on the date of the Change in Control and
ending three hundred sixty-five (365)&nbsp;days following the Change in Control; provided, however, that in the case of an Anticipatory Termination, the Protection Period shall also include the one hundred twenty (120)&nbsp;day period preceding the
Change of Control. For purposes of this Agreement, an &#147;Anticipatory Termination&#148; means a termination of Executive&#146;s employment without Substantial Cause in anticipation of a Change in Control (by reason of the request of the
individual, entity or other person (or their representatives) who subsequently acquires AXOGEN or INC. (the &#147;Acquirer&#148;)). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;For purposes of this Agreement, &#147;Substantial
Cause&#148; is the occurrence of any of the following during the course of Executive&#146;s employment with AXOGEN: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the commission by Employee of any act of fraud, theft, or embezzlement involving AXOGEN or INC.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any material breach by Executive of this Agreement or any other agreement between Executive and AXOGEN
(including the Confidentiality Agreement), provided that if such material breach is reasonably susceptible to cure, AXOGEN shall have first delivered to Executive written notice of the alleged breach, specifying the nature of the breach, and
provided, further, that Executive shall have failed to cure or substantially mitigate such breach within thirty (30)&nbsp;days after receiving such written notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a conviction of any felony, or of any misdemeanor involving moral turpitude, or entry of a plea of guilty or
nolo contendere to any felony or misdemeanor involving moral turpitude; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">willful and material failure to adhere to AXOGEN&#146;s or INC.&#146;s corporate codes, policies or procedures
which have been adopted in good faith for a valid business purpose as in effect from time to time. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;For
purposes of this Agreement, &#147;Good Reason&#148; shall mean Executive&#146;s resignation from employment, provided that Substantial Cause for termination of Executive&#146;s employment does not exist at the time of such resignation and the
resignation is the result of the occurrence of any one or more of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">a)&#8195;the assignment to Executive of any duties
materially inconsistent with Executive&#146;s (including status, offices, titles, and reporting requirements), authorities, duties, or other responsibilities or any other action of AXOGEN, INC., or the Acquirer that results in a material
diminishment in such position, authority, title, duties, or responsibilities, other than an insubstantial and/or inadvertent action which is remedied by AXOGEN, INC., or the Acquirer promptly after receipt of notice thereof given by Executive; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">b)&#8195;a reduction by AXOGEN, INC., or the Acquirer, absent Substantial Cause, in Executive&#146;s base salary as in effect on the date
hereof and as the same shall be increased from time to time hereafter; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">However, the foregoing events or conditions will constitute Good
Reason only if the Executive provides AXOGEN, INC., or the Acquirer with written objection to the event or condition within sixty (60)&nbsp;days following the occurrence thereof, AXOGEN, INC. and AXOGEN, INC. or the Acquirer does not reverse or
otherwise cure the event or condition within thirty (30)&nbsp;days of receiving that written objection and the Executive resigns the Executive&#146;s employment within ninety (90)&nbsp;days following the expiration of that cure period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(v)&#8195;<U>Termination not in Connection with a Change in Control</U>. In the event of Executive&#146;s termination of employment by AXOGEN
without Substantial Cause, or by Executive with Good Reason, is not in connection with a Change in Control, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Executive shall be entitled to a separation payment consisting of:
(a)&nbsp;fifteen (15) months of Executive&#146;s base salary; and (b) 125% of Executive&#146;s target bonus for the year in which the termination occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Payment of Separation Pay</U>. As a condition of receiving any separation pay under this Section&nbsp;4 (the &#147;Separation
Payment&#148;), Executive must first sign (and not revoke) a separation, waiver and release agreement (to be prepared by AXOGEN at the time of Executive&#146;s termination) (the &#147;Separation Agreement&#148;) of all claims (known and unknown)
against AXOGEN and INC., including claims arising out of or relating to Executive&#146;s employment with AXOGEN or termination thereof, excluding claims for separation pay under this Section&nbsp;4, as well as any other terms and conditions
reasonably required by AXOGEN. The Company will consider, in its sole discretion, offering a release to Executive in connection with the Separation Agreement. The Separation Payment will be made in a lump sum on the first payroll date following the
60th day following the date of Executive&#146;s execution (without revocation) of the Separation Agreement; provided, however, that if the <FONT STYLE="white-space:nowrap">60-day</FONT> period spans two (2)&nbsp;calendar years, the payments will
commence in the second calendar year. Notwithstanding the foregoing, if the Executive is a &#147;specified employee&#148; on Executive&#146;s termination date, the postponement provisions of Section&nbsp;409A of the Internal Revenue Code of 1986, as
amended (the &#147;Code&#148;), as described in Section&nbsp;6(n) below, shall apply, if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in the event Executive is
entitled to any Separation Payment pursuant to this Agreement and so long as AXOGEN or INC. is subject to federal COBRA and Executive timely elects continuation coverage under COBRA, AXOGEN or INC. shall pay Executive (i)&nbsp;a lump sum equal to
the value of Executive&#146;s and Executive&#146;s covered dependents&#146; health insurance premium equivalent to twenty-four (24)&nbsp;months in lieu of COBRA continuation in the event that the termination is in connection with a Change in Control
or a lump sum equal to the value of Executive&#146;s and Executive&#146;s covered dependents&#146; health insurance premium for eighteen (18)&nbsp;months in lieu of COBRA continuation in the event that the termination is not in connection with a
Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<U>Limitation on Payments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i)&#8195;Notwithstanding any other provision of this Agreement or any other plan, arrangement or agreement to the contrary, if any of the
payments or benefits provided or to be provided to Executive pursuant to the terms of this Agreement or otherwise (&#147;Covered Payments&#148;) constitute parachute payments within the meaning of Section&nbsp;280G of the Code and would, but for
this Section&nbsp;4(d) be subject to the excise tax imposed under Section&nbsp;4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to such taxes
(collectively, the &#147;Excise Tax&#148;), then prior to making the Covered Payments, a calculation shall be made comparing (a)&nbsp;the Net Benefit (as defined below) to the Employee of the Covered Payments after payment of the Excise Tax to
(b)&nbsp;the Net Benefit to the Employee if the Covered Payments are limited to the extent necessary to avoid being subject to the Excise Tax. Only if the amount calculated under (a)&nbsp;above is less than the amount under (b)&nbsp;above will the
Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax. &#147;Net Benefit&#148; shall mean the present value of the Covered Payments net of all federal, state,
local, foreign income, employment and excise taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;The Covered Payments shall be reduced in a manner that
maximizes the Executive&#146;s economic position. To the extent that Section&nbsp;409A of the Code is applicable, then in applying this principle, the reduction shall be made in a manner consistent with the requirements of Section&nbsp;409A of the
Code, and where two economically equivalent amounts are subject to reduction but payable at different times, such amounts shall be reduced on a pro rata basis but not below zero. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;Any determination required under this Section&nbsp;4(d) shall be made in writing in good faith by an independent accounting firm or
other independent consultant selected by AXOGEN (the &#147;Accountants&#148;) which shall provide detailed supporting calculations to AXOGEN and the Executive as requested by AXOGEN. AXOGEN and the Executive shall provide the Accountants with such
information and documents as the Accountants may reasonably request in order to make a determination under this Section&nbsp;4(d). For purposes of making the calculations and determinations required by this Section&nbsp;4(d), the Accountants may
rely on reasonable, good faith assumptions and approximations concerning the application of Section&nbsp;280G and Section&nbsp;4999 of the Code. The Accountants determinations shall be final and binding on AXOGEN and the Executive. AXOGEN shall be
responsible for all fees and expenses incurred by the Accountants in connection with the calculations required by this Section&nbsp;4(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;It is possible that after the determinations and selections made pursuant to this Section&nbsp;4(d) the Executive will receive
Covered Payments that are in the aggregate more than the amount provided under this Section (&#147;Overpayment&#148;) or less than the amount provided under this Section (&#147;Underpayment&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(v)&#8195;In the event that: (a)&nbsp;the Accountants determine, based upon the assertion of a deficiency by the Internal Revenue Service
against either AXOGEN or the Executive which the Accountants believe has a high probability of success, that an Overpayment has been made or (b)&nbsp;it is established pursuant to a final determination of a court or an Internal Revenue Service
proceeding that has been finally and conclusively resolved that an Overpayment has been made, then the Executive shall pay any such Overpayment to AXOGEN. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(vi)&#8195;In the event that: (a)&nbsp;the Accountants, based upon controlling precedent or substantial authority, determine that an
Underpayment has occurred or (b)&nbsp;a court of competent jurisdiction determines that an Underpayment has occurred, any such Underpayment will be paid promptly by AXOGEN to or for the benefit of the Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Surrender of Records and all AXOGEN and INC. Property</U>. Upon termination of Executive&#146;s employment with AXOGEN or INC for any reason, or
at any time as AXOGEN or INC. requests, Executive will immediately return to AXOGEN and INC., as applicable all Confidential Information and other tangible property that belongs to AXOGEN or INC. in Executive&#146;s possession; such tangible
property includes but is not limited to: all keys and security and credit cards; all products, product samples, computers, cellular phones and other electronic devices; and all customer and account files, price lists, product information, training
manuals, advertising and promotional materials, handbooks and polices (in physical or electronic format). Executive shall not retain possession of any copies of correspondence, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">memoranda, reports, notebooks, drawings, photographs notes, research and scientific
data, and tangible communications concerning the same, or other documents in any form whatsoever (including information contained in computer memory or any portable storage device (e.g., a &#147;thumb drive&#148;) relating in any way to the
Confidential Information obtained by or entrusted to Executive during Executive&#146;s employment. and confirm such return in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Miscellaneous Provisions</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendments to this Agreement only in Writing</U>. The provisions of this Agreement and the attached
Schedules and Exhibits shall only be modified by a written agreement executed by both a duly authorized officer of AXOGEN and Executive. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Assignments</U>. Executive shall not assign Executive&#146;s rights and/or obligations pursuant to this
Agreement or the attached Schedules and Exhibits. AXOGEN may not assign its rights and/or obligations pursuant to this Agreement and the attached Schedules and Exhibits at any time without Executive&#146;s written consent except to any successor to
AXOGEN or its assets, provided, however, any successor to AXOGEN or its assets shall agree in writing to comply with the terms and conditions set forth in this Agreement, including the assumption of all obligations required of AXOGEN. In the event
of a Change in Control in which AXOGEN or INC. is not the surviving entity, any reference to AXOGEN or INC. shall be deemed to refer to the surviving entity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Binding Effect</U>. All of the terms and provisions of this Agreement and the attached Schedules and
Exhibits, whether so expressed or not, shall be binding upon, inure to the benefit of, and be enforceable by the Parties and their respective administrators, executors, legal representatives, heirs, successors and permitted assigns.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>The Provisions of this Agreement are Severable</U>. If any part of this Agreement, or any of the Schedules
or Exhibits entered into pursuant to this Agreement, is contrary to, prohibited by, or deemed invalid under any applicable law or regulation, such provision shall be inapplicable and deemed omitted to the extent so contrary, prohibited or invalid,
but the remainder of this Agreement and its Schedules and Exhibits shall not be so invalidated, and shall be given full force and effect so far as possible. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Survival</U>. Notwithstanding anything to the contrary in this Agreement, the provisions of Sections 1
through 6 shall survive and remain in effect beyond the execution and delivery of this Agreement and termination of Executive&#146;s employment in accordance with their respective terms of duration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waivers</U>. The failure or delay of AXOGEN or Executive at any time to require performance of any provision
of this Agreement or the attached Schedules and Exhibits, even if known, shall not affect the rights of AXOGEN or Executive to require performance of that provision or to exercise any right, power or remedy pursuant to this Agreement or the attached
Schedules and Exhibits. Any waiver by AXOGEN or Executive of any breach of any provision of this Agreement or the attached Schedules and Exhibits shall not be construed as a waiver of any continuing or succeeding breach of such provision, a waiver
of the provision itself, or a waiver of any right, power or remedy pursuant to this Agreement or the attached Schedules and Exhibits. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices</U>. All notices, requests, consents and other communications required or permitted under this
Agreement shall be in writing and shall be (i)&nbsp;delivered via electronic notification; (ii)&nbsp;hand-delivered by messenger or courier service; or (iii)&nbsp;sent by an overnight-mail service (e.g. FedEx or UPS);), return receipt requested, and
addressed to: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>If to Executive:</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Executive&#146;s most current address on file with AXOGEN, Executive&#146;s current address being: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Michael Dale </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">183 Scenic Range
Court </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Carson City, Nevada 89705 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="65%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If to AXOGEN:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>With a copy to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">AXOGEN Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>AXOGEN Corporation</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">13631 Progress Blvd., Ste. 400</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13631 Progress Blvd., Ste. 400</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Alachua, FL 32615</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Alachua, FL 32615</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn: Office of the General Counsel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Attn: Human Resources</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">or to such other address as any party may designate by written notice complying with the terms of this Section.
Each such notice shall be deemed delivered (a)&nbsp;on the date delivered, if by personal delivery, or (b)&nbsp;on the date upon which the return receipt is signed, or delivery is refused. <U>Governing Law</U>. This Agreement and the attached
Schedules and Exhibits and all transactions contemplated by this Agreement or the attached Schedules and Exhibits shall be governed by, and construed and enforced in accordance with, the laws of the state in which Employee is most recently
continually employed by AXOGEN for a thirty (30)&nbsp;day period, provided that until Employee has been employed by AXOGEN for less than thirty (30)&nbsp;days, the law of the State of California shall be deemed to apply to this Agreement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Remedies Available to Either Party Cumulative</U>. No remedy conferred upon any party pursuant to this
Agreement (or the attached Schedules and Exhibits) is intended to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to every other remedy given pursuant to this Agreement (or the attached
Schedules and Exhibits) now or hereafter existing at law or in equity or by statute or otherwise. No single or partial exercise by any party of any right, power or remedy pursuant to this Agreement (or the attached Schedules and Exhibits) shall
preclude any other or further exercise of such right, power or remedy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement</U>. This Agreement and the attached Schedules and Exhibits represents the entire
understanding and agreement between the Parties with respect to the subject matter contained herein and supersedes all other agreements, negotiations, understandings and representations (if any) made by
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">and between the Parties regarding such subject matter (including any offer letter between Employee and AXOGEN). The Parties represent that they have not relied on any statement, promise, or representation not set forth
herein in entering into this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Section and Paragraph Headings</U>. Section and paragraph headings used throughout this Agreement and the
attached Schedules and Exhibits are for convenience of reference only and in no way define, limit or describe the scope or intent of this Agreement or the attached Schedules and Exhibits. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Preparation of Agreement</U>. This Agreement shall not be construed more strongly against any party
regardless of who is responsible for its preparation. The Parties acknowledge that each party contributed to its negotiations and is equally responsible for its preparation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Section&nbsp;409A of the Code</U>. Notwithstanding any provision of this Agreement to the contrary, this
Agreement is intended to meet the requirements of Section&nbsp;409A of the Code to the extent applicable, the Parties intend to administer this Agreement in a manner that is consistent with those requirements or an exception thereto, and this
Agreement shall be construed and interpreted in accordance with such intent. Any payments that are considered deferred compensation under Section&nbsp;409A of the Code and that are paid to a &#147;specified employee&#148; (as defined in
Section&nbsp;409A of the Code) upon separation from service shall be subject to a six (6)&nbsp;month delay, if required by Section&nbsp;409A of the Code. If required by Section&nbsp;409A of the Code, any amounts otherwise payable during the six
(6)&nbsp;month period that commences on and follows the Executive&#146;s termination date shall be paid in one lump sum amount on the first payroll date following the six (6)&nbsp;month period following the Executive date of termination (or within
thirty (30)&nbsp;days of the Executive&#146;s death, if earlier). For purposes of Section&nbsp;409A of the Code, all payments to be made upon a termination of employment under this Agreement may only be made upon a &#147;separation from
service&#148; (within the meaning of such term under Section&nbsp;409A of the Code). Each payment made under this Agreement shall be treated as a separate payment. In no event shall the Executive, directly or indirectly, designate the calendar year
of a payment. All reimbursements under this Agreement shall be provided in a manner that complies with Section&nbsp;409A of the Code, if applicable. If required by regulations or other guidance issued under Section&nbsp;409A of the Code or a court
of competent jurisdiction, the provisions regarding payments hereunder shall be amended to provide for such payments to be made at the time allowed under such regulations, guidance or authority that most closely achieves the intent of this
Agreement. If Executive or AXOGEN believes, at any time, that any such payment is subject to the Section&nbsp;409A Tax, it shall advise the other and Executive and AXOGEN shall reasonably cooperate in good faith to take such steps as necessary,
including amending (and, as required, consenting to the amendment of) the terms of any plan or program under which the payments are to be made, including this Agreement, to avoid the imposition of a Section&nbsp;409A tax, in each case, without any
material diminution in the value of the payments or benefits to Executive. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Liability Insurance</U>. AXOGEN shall cover, at its sole cost and expense, the Executive under directors and
officers liability insurance both during the term of this Agreement and for the three year period following the termination of this Agreement, in the same amount and to the same extent as AXOGEN covers its officers and directors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indemnification. The Executive shall be indemnified to the fullest extent permitted under the Company&#146;s <FONT
STYLE="white-space:nowrap">By-Laws.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Follow] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPLOYEE AND AXOGEN</B> have executed this Agreement as of the 9th day of August,
2024. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AXOGEN CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Began</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Marc Began</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Executive Vice President,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General Counsel and Chief Compliance&nbsp;Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Dale</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Michael Dale</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE AND EXHIBIT LIST </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 - Duties of Employee </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 2 - Compensation and
Benefits </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit A - Confidentiality, Intellectual Property, <FONT STYLE="white-space:nowrap">Non-Competition</FONT> and
<FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 - DUTIES OF EMPLOYEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The duties of Executive with AXOGEN CORPORATION (&#147;AXOGEN&#148;) are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Executive&#146;s Title</U>: AXOGEN hereby employs Executive as Chief Executive Officer (the
&#147;CEO&#148;), which title may change by written agreement between the parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Executive&#146;s Duties</U>: Executive shall perform all duties in connection with Executive&#146;s
position, or as otherwise designated by AXOGEN, including, without limitation, the following duties: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Reporting to
AXOGEN&#146;s Board of Directors (the &#147;Board&#148;), the CEO<I> </I>is the most senior member of AXOGEN&#146;s executive leadership team with a high degree of visibility and impact across the organization. This role, collaborating with the
Board and senior leaders across the organization, brings a strong strategic and visionary mindset and is a key contributor to the overall corporate strategy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Primary Responsibilities: The specific duties of the CEO<I> </I>include but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Setting overall leadership and direction of Axogen; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Supervising other senior executives; <U>and</U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any other duties as needed by the Board and the company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compliance with Employee Policies, Procedures, Rules and Regulations</U>: Executive shall comply with all
AXOGEN policies, procedures, rules and regulations for employees as such policies and procedures may exist or be established from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Other Business Activities</U>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Executive shall devote Executive&#146;s entire professional time, energy and skill to the performance of
Executive&#146;s duties pursuant to the Agreement, the service of AXOGEN, and promotion of AXOGEN&#146;s interests. The Parties agree that Executive may not during Employee&#146;s employment, except as permitted in writing by AXOGEN, be engaged in
any other business activity, whether or not such activity is pursued for gain, profit, or other pecuniary advantage including, without limitation, management or management consulting activities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Notwithstanding the preceding subsection, subject to any conflict of interest policies of AXOGEN and so long as
the following do not interfere with the performance of Executive&#146;s duties hereunder, Executive (i)&nbsp;upon approval by the Board, which approval shall not be unreasonably withheld, may serve on the boards of directors of up to two <FONT
STYLE="white-space:nowrap">for-profit</FONT> business enterprises that are not competitive with AXOGEN, (ii)&nbsp;may serve in any capacity with any civic, charitable, educational or professional organization, (iii)&nbsp;may make and manage personal
investments of Executive&#146;s choice, and (iv)&nbsp;Executive may invest Executive&#146;s personal assets in businesses or real estate that are not in competition with AXOGEN where the form or manner of such investment will not require services on
the part of Executive, and in which Executive&#146;s participation is solely that of a passive investor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 - COMPENSATION AND BENEFITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the EXECUTIVE EMPLOYMENT AGREEMENT (the &#147;Agreement&#148;), Executive may be entitled to receive
from AXOGEN Corporation (&#147;AXOGEN&#148;) the following compensation and benefits: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Base Salary</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Amount</U>. Executive&#146;s salary during employment with AXOGEN will be at the rate of seven hundred sixty-five thousand dollars
($765,000.00) annually, (the &#147;Base Salary&#148;), prorated for partial years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Payment</U>. The Base Salary shall be
payable in accordance with the existing payroll practices of AXOGEN, which practices may be changed by AXOGEN from time to time at its sole discretion. The Base Salary shall be subject to all appropriate withholding taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Review of Base Salary</U>. The Base Salary may be reviewed by AXOGEN from time to time; however, AXOGEN reserves the right to
increase the Base Salary at any time during the employment relationship in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Business Expenses and Reimbursements</U>.
Executive shall be eligible for reimbursement by AXOGEN in accordance with AXOGEN&#146;s normal reimbursement practices for ordinary and necessary business expenses incurred by Executive in the performance of Executive&#146;s duties for AXOGEN, so
long as Executive timely submits to AXOGEN accurate invoices and receipts of all expenses submitted for reimbursement pursuant to this section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Benefits</U>. Executive will be permitted to participate in such senior executive benefit plans of AXOGEN that may be in effect from time to time,
to the extent Executive is eligible under the terms of those plans. Nothing herein shall be construed to require AXOGEN to institute or continue any particular plan or benefit. AXOGEN reserves the right to add, change, or eliminate any benefits at
any time at its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Vacations and Holidays</U>. Executive will be entitled to paid vacation of 4 weeks per calendar year and
holidays in accordance with the holiday policies of AXOGEN in effect for its employees from time to time. Vacation must be taken by Executive at such time or times as approved by AXOGEN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Bonus</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Calculation</U>. For the 2024 calendar year, Executive shall be eligible to receive an annual bonus (the &#147;2024 Annual
Bonus&#148;), the target amount of which shall equal one hundred percent (100%) of the Base Salary (prior to proration). The 2024 Annual Bonus shall be prorated based on the number of days between the Effective Date of the Agreement and
December&nbsp;31, 2024. For the 2025 calendar year and subsequent calendar years, Executive shall be eligible to receive an annual bonus (the &#147;Subsequent Annual Bonuses&#148;), the target amount of each such Subsequent Annual Bonus shall be
determined on an annual basis by the Compensation Committee of AXOGEN&#146;s Board of Directors (the &#147;Compensation Committee&#148;) in its sole direction. The 2024 Annual Bonus and Subsequent Annual Bonuses shall be based on either
(i)&nbsp;solely AXOGEN&#146;s performance or (ii)&nbsp;a combination of AXOGEN&#146;s performance and the achievement of department-level goals, as determined by the Compensation Committee in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Payment</U>. The Bonus if paid shall be paid in accordance
with, and subject to, the normal payroll policies of AXOGEN with respect to similar forms of compensation, including, without limitation, being subject to all appropriate withholding taxes. In order to be eligible to earn and receive the 2024 Annual
Bonus, Employee must be employed by AXOGEN through the date any such bonus is paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Equity</U>. Executive shall be eligible to receive inducement
equity incentive grants in the form of 600,000 Performance Stock Units (the &#147;PSUs&#148;), subject to and contingent upon the approval of the Compensation Committee. The PSUs, if any are approved and granted, shall be subject to time-vesting and
performance-vesting conditions, as determined by the Compensation Committee and as set forth in the applicable award agreements. Executive shall be eligible to receive annual equity awards starting in 2025, as determined by the Compensation
Committee in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Compensation Review</U>. AXOGEN may, from time to time, review Executive&#146;s compensation (including
benefits) and may, in its sole discretion, increase, or decrease, or eliminate any or all of the benefits. Any such increase or decrease in the compensation package shall be in writing, executed by a duly authorized officer of AXOGEN, and such
writing shall constitute an amendment to this Paragraph 7 (and to the Agreement and any applicable Schedules or Exhibits) solely as to the benefits, without waiver or modification of any other terms, conditions or provisions of the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>No Other Compensation</U>. Executive agrees that the compensation and benefits set forth in the Agreement and this Schedule 2 contain the sole and
exclusive compensation and benefits to which Executive is eligible and that Executive shall have no rights to receive any other compensation or benefits of any nature from AXOGEN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY, INTELLECTUAL PROPERTY, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">NON-COMPETITION</FONT> AND <FONT STYLE="white-space:nowrap">NON-SOLICITATION</FONT> AGREEMENT
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Confidentiality, Intellectual Property, <FONT STYLE="white-space:nowrap">Non-Competition</FONT> and
<FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement (this &#147;IP and NCNS Agreement&#148;) is effective as of August&nbsp;9, 2024 (the &#147;Effective Date&#148;) by and between Axogen Corporation, having a place of business at
13631 Progress Blvd., Suite 400, Alachua, FL 32615 (together with Axogen, Inc, referred to herein as &#147;Axogen&#148;) and Michael Dale (&#147;Employee&#148;). Axogen and Employee may each be referred to herein as a &#147;Party&#148; and
collectively as the &#147;Parties&#148;. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Axogen is a global leader in developing, marketing, selling and distributing surgical and <FONT STYLE="white-space:nowrap">non-surgical</FONT>
solutions for peripheral nerve damage or discontinuity, as well as of instruments and devices in connection with the foregoing and in diagnosis, surgery for, therapy associated with and recovery in connection with nerve damage and/or nerve
discontinuity, and has spent substantial time, resources and monies developing its Confidential Information (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Employee
has accepted employment with or is currently an employee of Axogen who will or does, as the case may be, receive certain compensation and other employment-related benefits from Axogen in return for Employee performing Employee&#146;s job duties and
responsibilities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, during Employee&#146;s employment Employee will be (or has been) provided with periodically supplemented Confidential
Information, including trade secrets, as well as the opportunity to contribute to the creation and/or maintenance of Confidential Information; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Employee recognizes that Axogen&#146;s Confidential Information is an important and valuable asset to Axogen and that Axogen has a legitimate
business interest in protecting these assets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> Employee recognizes that Axogen&#146;s relationships with Axogen Customers and the goodwill
associated with Axogen Customers, Axogen&#146;s business and Axogen&#146;s reputation in the industry, are important and valuable assets to Axogen and that Axogen has a legitimate business interest in protecting those assets; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in consideration for Employee&#146;s initial employment or continued employment, as the case may be, with Axogen, Employee agrees to abide by
the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE,</B> in consideration of the mutual covenants contained herein and other good and valuable
consideration, including initial or continued employment, the receipt and sufficiency of which are hereby acknowledged, the Parties to this IP and NCNS Agreement hereby agree as follows: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>DEFINITIONS</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following terms, when used in this IP and NCNS Agreement with initial capital letters, shall have the respective meanings set forth in this Section&nbsp;1.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Axogen Customers</U>&#148; means accounts, customers,
physicians, therapists, hospitals, acute surgical care centers, group purchasing organizations, integrated delivery networks, treatment centers or other clients that: (a)&nbsp;have purchased Axogen products during the prior one (1)&nbsp;year; or
(b)&nbsp;have received or requested a proposal during the prior one (1)&nbsp;year for the purchase Axogen products; as well as all such entities or individuals that come to purchase Axogen products and/or request or receive a proposal for the
purchase of Axogen products during the time of Employee&#146;s employment by Axogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Competing Organization</U>&#148; means any
person or organization which is engaged in or actively preparing to become engaged in research on, consulting regarding, or development, production, marketing or selling of a Competing Product including, but not limited to, the organizations
identified on <U>Schedule 1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Competing Product</U>&#148; means any product, process, technology, service, machine or
invention of any person or organization other than Axogen in existence or under development which competes with, is substitutable for, or is intended to compete with, or be substitutable for, a product, process, technology, service, machine or
invention developed of offered by Axogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Confidential Information</U>&#148; means Axogen&#146;s confidential, proprietary,
trade secret or any other <FONT STYLE="white-space:nowrap">non-public</FONT> information, including without limitation <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to: (a)&nbsp;Axogen Customers; (b)&nbsp;actual or
potential vendors, suppliers, distributors or referral sources; (c)&nbsp;products, product manufacturing and distribution systems and processes, product technology, product development plans and strategies; (d)&nbsp;marketing and sales strategies
and plans, product pricing policies, offerings and structures; (e)&nbsp;business and financial information of a <FONT STYLE="white-space:nowrap">non-public</FONT> nature (e.g., strategy plans, forecasts, budgets); (f) employee, personnel or payroll
policies, records and information; (g)&nbsp;corporate development strategies including acquisitions, divestitures, growth plans and other plans; (h)&nbsp;clinical study design, management, evaluation, and interpretation; (i)&nbsp;inventions, ideas,
innovations, improvements, <FONT STYLE="white-space:nowrap">know-how,</FONT> methods, processes, specifications, procedures, invention disclosures, certifications, and proposed and/or actual research and development activities, regardless of whether
or not any of the foregoing is patentable or otherwise protectable under the intellectual property laws of the United States; and (j)&nbsp;information disclosed by third parties to Axogen pursuant to a confidentiality agreement. Confidential
Information does not include information that is or becomes part of the public domain through no fault of Employee, or without any third-party violation of any confidentiality agreement with Axogen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Copyrightable Works</U>&#148; means all works of authorship, fixed in any tangible medium of expression known or later developed,
including but not limited to writings, reports, articles, white papers, compilations, summaries, graphics, computer programs, user interfaces, drawings, designs, documentation and publications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Extended Restricted Period</U>&#148; means the period of Employee&#146;s employment by Axogen and for a period of fifteen months
(15)&nbsp;months following the termination of Employee&#146;s employment with Axogen for any reason; provided that if Employee is primarily employed by Axogen (with Axogen&#146;s consent) within the State of California during the then most-recent
thirty (30)&nbsp;days of Employee&#146;s employment by Axogen (or during Employee&#146;s employment if employed less than 30 days), the term <U>Extended Restricted Period shall mean only</U> the period of Employee&#146;s employment by Axogen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; means all inventions, patents,
patent applications, designs, discoveries, ideas, innovations, improvements, modifications, trade secrets, methods, processes, specifications, procedures, trademarks, certifications, and invention disclosures, whether or not patentable or otherwise
protectable under the intellectual property laws of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Contact</U>&#148; means (i)&nbsp;any interaction
between Employee and an Axogen Customer which takes place in an effort to establish, maintain, and/or further a business relationship on behalf of Axogen, (ii)&nbsp;any Axogen Customer whose dealings with Axogen were coordinated or supervised by
Employee, (iii)&nbsp;any Axogen Customer about whom Employee obtained Confidential Information in the ordinary course of business as result of Employee&#146;s association with Axogen, or (iv)&nbsp;any Axogen Customer who receives product or services
from Axogen, the sale or provision of which results or resulted in compensation, commissions or earnings for Employee, all within the then post-recent year of Employee&#146;s employment with Axogen (or during Employee&#146;s employment if employed
less than a year). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Restricted Period</U>&#148; means the period of Employee&#146;s employment by Axogen and for a period of one
(1)&nbsp;year following the termination of Employee&#146;s employment with Axogen for any reason; provided that if Employee is primarily employed by Axogen (with Axogen&#146;s consent) within the State of California during the then most-recent
thirty (30)&nbsp;days of Employee&#146;s employment by Axogen (or during Employee&#146;s employment if employed less than 30 days), the term <U>Restricted Period shall mean only</U> the period of Employee&#146;s employment by Axogen. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>CONFIDENTIAL INFORMATION AND PROPERTY</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1.&#8195;<U><FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> of Confidential Information</U>. Employee acknowledges that the
Confidential Information is of great value to Axogen, that Axogen has legitimate business interests in protecting its Confidential Information, and that the disclosure to anyone not authorized to receive such information, including any Competing
Organization, will cause irreparable injury to Axogen. Employee agrees: (a)&nbsp;not to make use of the Confidential Information for any purpose other than is necessary to perform Employee&#146;s duties while an employee of Axogen; (b)&nbsp;not to
disclose, use, disseminate, identify, or publish Confidential Information for five (5)&nbsp;years after the termination of Employee&#146;s employment with Axogen for any reason; (c)&nbsp;to provide to Axogen&#146;s Office of General Counsel
immediate notice of any (i)&nbsp;inadvertent or otherwise improper disclosure of Confidential Information; and (ii)&nbsp;theft of Confidential Information, including breach of security, hacking, or other improper act by a third party.
Notwithstanding the foregoing, Employee agrees not to, and shall not for any reason disclose, use, disseminate, identify or publish Confidential Information that is an Axogen trade secret, as long as that Confidential Information remains a trade
secret and does not become publicly known through no fault of Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2.&#8195;<U>Return of Confidential Information and Axogen
Property</U>. Upon termination of Employee&#146;s employment with Axogen for any reason, or at any time as Axogen requests, Employee shall immediately return to Axogen all Confidential Information and other tangible property that belongs to Axogen
in Employee&#146;s possession; such tangible property includes but is not limited to: all keys and security and credit cards; all products, product samples, computers, cellular phones and other electronic devices; and all customer and account files,
price lists, product information, training manuals, advertising and promotional materials, handbooks and polices (in physical or electronic format). Employee shall not retain possession of any physical or electronic copies of correspondence,
memoranda, reports, notebooks, drawings, photographs notes, research and scientific data, and tangible communications concerning the same, or other documents in any form whatsoever (including information contained in computer memory or any portable
storage device (e.g., a &#147;thumb drive&#148;) relating to or reflecting in any way to the Confidential Information obtained by or entrusted to Employee during Employee&#146;s employment with Axogen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&#8195;<U>Defend Trade Secrets Act</U>. Pursuant to the Defend Trade
Secrets Act of 2016, 18 U.S.C. &#167;1833, Employee acknowledges that Employee shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A)&nbsp;is made (i)&nbsp;in confidence
to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint or other document
filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, if Employee files a lawsuit for retaliation by Axogen for reporting a suspected violation of law, Employee shall not have criminal or civil liability under any
federal or state trade secret law if Employee discloses the trade secret to Employee&#146;s attorney and (X)&nbsp;files any document containing the trade secret under seal and (Y)&nbsp;does not disclose the trade secret, except pursuant to court
order. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>RESTRICTIVE COVENANTS</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1.&#8195;<U>Employee Acknowledgment</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Employee acknowledges that: (a)&nbsp;Employee&#146;s position and employment with Axogen gives Employee access to and knowledge of
Axogen Customers and its vendors, suppliers, distributors or referral sources (collectively, &#147;<U>Axogen Business Partners</U>&#148;), which represent important and unique business assets that have resulted from a significant investment of time,
resources and monies by Axogen; (b)&nbsp;Employee would cause Axogen great loss, damage and immediate irreparable harm if Employee were to engage in unfair or unlawful competitive activity by improperly using or disclosing any information related to
Axogen Business Partners for Employee&#146;s own benefit or for the benefit of any Competing Organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Employee
acknowledges and agrees that the restrictions contained in this Section&nbsp;3, may be reasonable and necessary to protect Axogen&#146;s legitimate business interests, promote and protect the purpose and subject matter of this IP and NCNS Agreement
and Employee&#146;s employment, and deter any potential conflict of interest. Employee agrees that Employee knows of no reason at the time of singing this Agreement why any restriction contained in this Section&nbsp;3 is not reasonable and
enforceable and that all such restrictions may be necessary and reasonable to protect Axogen&#146;s interests. Employee also acknowledges and agrees that the restrictions contained in this Section&nbsp;3&nbsp;may not impair or infringe upon
Employee&#146;s right to work or earn a living when Employee&#146;s employment with Axogen ends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&#8195;<U><FONT
STYLE="white-space:nowrap">Non-Compete</FONT></U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;During the Restricted Period, Employee will not work for (as an employee,
consultant, contractor, agent or otherwise) or render services directly or indirectly to any Competing Organization whereby the services Employee would provide for, to, or on behalf of the Competing Organization (i)&nbsp;are the same as or similar
to those services that Employee provided for, to, or on behalf of Axogen during Employee&#146;s employment, (ii)&nbsp;involve the development, sale, marketing, or distribution of a Competing Product, or (iii)&nbsp;could enhance the use or
marketability of a Competing Product. This restriction covers (i)&nbsp;the United States, (ii)&nbsp;any state or territory in which Axogen is engaged in its business at the time of and during the then most recent one year of Employee&#146;s
employment with Axogen (or during Employee&#146;s employment if employed less than a year), and (iii)&nbsp;any state or territory in which Employee was providing services for Axogen at the time of and during the year prior to Employee&#146;s
separation from Axogen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;The restrictions herein shall not prohibit Employee from
accepting employment with a Competing Organization whose business is diversified and which is, as to that part of its business in which Employee accepts employment, not a Competing Organization. If Employee accepts employment with a Competing
Organization, Employee will provide Axogen written assurances satisfactory to Axogen that Employee will not render services, directly or indirectly, for the time period herein in connection with any Competing Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3&#8195;<U><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> of Employees and Axogen Business Partners</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;During the Extended Restricted Period, Employee will not in any capacity, directly or indirectly, solicit, induce or influence, or
attempt to solicit, induce or influence, any person engaged as an employee, independent contractor, or agent of Axogen to terminate his or her employment and/or business relationship with Axogen or do any act which may result in the impairment of
the relationship between Axogen and its employees, independent contractors or agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;During the Restricted Period, Employee
will not in any capacity, directly or indirectly: (i)&nbsp;solicit, contact, accept solicited business from, provide competitive services to, or sell any Competing Product to an Axogen Customer; (ii)&nbsp;divert, entice or otherwise take away from
Axogen the business or patronage of any Axogen Business Partner; or (iii)&nbsp;solicit or induce any Axogen Business Partner to terminate or reduce its relationship with Axogen or otherwise interfere with Axogen&#146;s relationship with any Axogen
Business Partner. This restriction applies only to those Axogen Customers and Axogen Business Partners with whom Employee had Material Contact. In the event Employee is primarily employed by Axogen in Nevada in the final thirty (30)&nbsp;days of
Employee&#146;s employment by Axogen, then this Section&nbsp;3.3(b) shall not restrict Employee from providing a service following employment by Axogen to a former customer or client of Axogen if: (i)&nbsp;Employee did not solicit the former
customer or client; (ii)&nbsp;the customer or client voluntarily chose to leave and seek services from Employee; and (iii)&nbsp;Employee is otherwise complying with the limitations set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4&#8195;<U>New Employer Notification</U>. To enable Axogen to monitor Employee&#146;s compliance with the obligations set forth in this IP
and NCNS Agreement, Employee agrees to notify Axogen in writing before commencing employment with a new employer; such notification shall include the identify of Employee&#146;s new employer, job title and responsibilities. Employee will continue to
notify Axogen, in writing, any time Employee accepts or changes employment during the time periods set forth in this Section&nbsp;3. Employee agrees that Axogen is permitted to contact any new or prospective employer regarding Employee&#146;s
obligations owed to Axogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5&#8195;<U>Modification of <FONT STYLE="white-space:nowrap">Non-Compete</FONT> and <FONT
STYLE="white-space:nowrap">Non-Solicitation</FONT> Provisions</U>. The parties agree that a court of competent jurisdiction may modify any invalid, overbroad or unenforceable term of this Section&nbsp;3 so that such term, as modified, is valid and
enforceable under applicable law; such court is also authorized to extend the time periods set forth in this Section&nbsp;3 for any period of time in which Employee is in breach of this IP and NCNS Agreement or as necessary to protect the legitimate
business interests of Axogen. If a court of competent jurisdiction determines that any term of this Section&nbsp;3 is invalid, overbroad, or unenforceable, in whole or in part, and cannot be modified as set forth in the prior sentence to make such
term valid and enforceable under applicable law, the Parties agree that any such term, in whole or in part as the case may, shall be severable and the remainder of this Section&nbsp;3 and this IP and NCNS Agreement shall nevertheless be enforceable
and binding on the Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>INVENTIONS.</U> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1.&#8195;<U>Disclosure of Developments</U>. Employee agrees that during and subsequent to Employee&#146;s employment with Axogen, Employee
will promptly disclose and furnish complete information to Axogen relating to all inventions, ideas, improvements, modifications, discoveries, research, data, <FONT STYLE="white-space:nowrap">know-how,</FONT> methods and developments, whether
patentable or not, and whether or not otherwise protectable under the intellectual property laws of the United States, that are made, conceived, developed, reduced to practice, or authored by Employee or under Employee&#146;s direction during
Employee&#146;s employment whether or not made, conceived, developed, reduced to practice or authored during normal business hours or on Axogen premises. Employee shall keep complete, accurate, and organized information and records of all
Copyrightable Works or other Intellectual Property and Confidential Information in the manner and form reasonably requested by Axogen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&#8195;<U>Ownership of Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195; Employee agrees to assign and hereby does assign to Axogen all right, title and interest, worldwide in and to any and all
Intellectual Property made, conceived, developed, reduced to practice or authored by Employee alone or with others for AXOGEN during the course of Employee&#146;s employment (or after the period of Employee&#146;s employment and which rely upon or
use Axogen&#146;s Confidential Information and/or <FONT STYLE="white-space:nowrap">non-public</FONT> Intellectual Property), whether made, conceived, developed or reduced to practice, whether or not the foregoing are within the scope of
Axogen&#146;s actual or anticipated research and development business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Axogen&#146;s rights in Section&nbsp;4.2(a) above shall
not apply to any Intellectual Property conceived and developed without reliance upon and/or without the use of Axogen&#146;s equipment, supplies, facilities, Confidential Information or other <FONT STYLE="white-space:nowrap">non-public</FONT>
Intellectual Property, and which was developed entirely on Employee&#146;s own time, unless (a)&nbsp;the Intellectual Property relates (i)&nbsp;to Axogen&#146;s actual or anticipated business; (ii)&nbsp;to Axogen&#146;s actual or anticipated
research and development; or (iii)&nbsp;the Intellectual Property results from or relates to any work performed by Employee for Axogen. Employee understands that in accordance with Section&nbsp;2870(a) of the California Civil Code, any provision in
an agreement which provides that Employee shall assign, or offer to assign, any of his rights in an invention to Axogen shall not apply to an invention that Employee developed entirely on his own time without using Axogen&#146;s equipment, supplies,
facilities, or trade secret information, except for those inventions that either: (1)&nbsp;relate at the time of conception or use to Axogen&#146;s business, or actual or demonstrably anticipated research or development of Axogen; or (2)&nbsp;result
from any work Employee performs for Axogen. All Intellectual Property that falls within the scope of Section&nbsp;2870(a) of the California Civil Code shall be excluded from the assignment in Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For avoidance of doubt, it shall be Axogen&#146;s sole decision, in its sole discretion how to protect its Confidential Information and/or
Intellectual Property and/or Copyrightable Works and whether to formally seek registration of any of its Intellectual Property and/or Copyrightable Works. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&#8195;<U>Copyrightable Works</U>. Employee acknowledges that all Copyrightable Works shall to the fullest extent permissible be considered
&#147;works for hire&#148; in the United States as defined in the U.S. Copyright Laws and in any other country adhering to the &#147;works made for hire&#148; or similar notion. All such Copyrightable Works shall from the time of creation be owned
solely and exclusively by Axogen throughout the world. If any Copyrightable Work or portion thereof shall not be legally qualified as a work made for hire in the United States or elsewhere or shall subsequently be held to not be a work made for
hire, Employee agrees to assign and does hereby assign to Axogen all Employee&#146;s right, title and interest in, including all moral rights in and to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copyrightable Works, and all registered and applied for copyrights therein. To the
extent the assignment of all rights, title and interest in, including of all moral rights in, the Copyrightable Works, is prohibited in full or in part by any applicable law, Employee hereby grants to Axogen a
<FONT STYLE="white-space:nowrap">fully-paid-up,</FONT> royalty-free, exclusive, sublicensable, transferrable, irrevocable and perpetual, worldwide license in and to the Copyrightable Works and hereby waives Employee&#146;s enforcement of any moral
rights which Employee may hold in any existing or future Copyrightable Works worldwide and hereby consents to any action of Axogen that would violate its moral rights in the absence of such consent. Employee hereby further agrees that Axogen is not
required to designate Employee as author of any Copyrightable Works when such Copyrightable Works are distributed publicly or otherwise, and hereby waives any cause of action against Axogen for not so identifying Employee as an author of such
Copyrightable Works. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4&#8195;<U>License</U>. In the event that any of the rights in any Copyrightable Works or other Intellectual
Property (&#147;<U>Intellectual Property Rights</U>&#148;) cannot be transferred to Axogen pursuant to the terms of this IP and NCNS Agreement, Employee hereby (i)&nbsp;unconditionally and irrevocably waives the enforcement of any Intellectual
Property Rights retained by Employee, and all claims and causes of action of any kind against Axogen with respect to those rights; and (ii)&nbsp;grants to Axogen an irrevocable, perpetual, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT>
transferable, sublicensable, royalty-free, exclusive worldwide right and license to use, reproduce, distribute, display, perform, prepare derivative works of, modify, enforce, and otherwise use and exploit all or any portion of such existing and
future Intellectual Property Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5&#8195;<U>Causes of Action</U>. Employee further irrevocably assigns to Axogen all causes of
action, including accrued, existing and future causes of action, arising out of or related to the Intellectual Property Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6&#8195;<U>Cooperation</U>. When requested to do so by Axogen, either during or subsequent to Employee&#146;s employment with Axogen,
Employee shall: (a)&nbsp;execute all documents requested by Axogen for the vesting in Axogen of the entire right, title and interest in and to the Intellectual Property and Confidential Information, and all patent, copyright, trademarks or other
applications filed and issuing on the Intellectual Property; (b)&nbsp;execute all documents requested by Axogen for filing and obtaining of patents, trademarks or copyrights; and (c)&nbsp;provide assistance that Axogen reasonably requires to protect
its right, title and interest in the Intellectual Property and Confidential Information. Employee acknowledges that the obligations herein shall continue beyond the termination of Employee&#146;s employment with Axogen with respect to Intellectual
Property conceived, authored or made by Employee during Employee&#146;s period of employment and shall be binding on Employee&#146;s executors, administrators or other legal representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7&#8195;<U>Appointment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Attorney-In-Fact.</FONT></FONT></U> Employee
irrevocably appoints any AXOGEN-selected designee to act, at all times hereafter, as Employee&#146;s agent and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to perform all acts necessary to file for
registration of and/or register Copyrightable Works or other Intellectual Property as required by this IP and NCNS Agreement if Employee (i)&nbsp;refuses to perform those acts or (ii)&nbsp;is unavailable, within the meaning of the United States
Patent and Copyright laws. It is expressly intended by Employee that the foregoing power of attorney is coupled with an interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8&#8195;<U>Assignability</U>. All Intellectual Property Rights and representations made or granted by Employee in this IP and NCNS Agreement
are assignable by Axogen and are for the benefit of Axogen&#146;s successors, assigns, and parties contracting with Axogen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9&#8195;<U>Prior Intellectual Property</U>. Attached as <U>Schedule
2</U> is a complete list, if any, of all of Employee&#146;s Intellectual Property and Copyrightable Works made, conceived or first reduced to practice by Employee, alone or jointly with others, prior to Employee&#146;s employment with Axogen
(&#147;<U>Prior Intellectual Property</U>&#148;). If in the course of Employee&#146;s employment with Axogen Employee incorporates into an Axogen product, process or machine any Prior Intellectual Property to which Employee possesses all right,
title and interest, then Employee hereby grants, and agrees to grant, Axogen a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free, irrevocable, perpetual, transferable, sublicensable worldwide license to make, modify, use and sell
such Prior Intellectual Property as part of or in connection with such product, process or machine. Notwithstanding the foregoing, Employee agrees not to, and shall not, use at or on behalf of Axogen any Prior Intellectual Property that is owned by
a third party and/or the use of which would require a license from a third party, and/or to which Axogen has not otherwise acquired the right to use, and/or which would be in violation of Section&nbsp;5.3 of this IP and NCNS Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>EMPLOYEE REPRESENTATIONS</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1.&#8195;<U>Performance</U>. During Employee&#146;s employment with Axogen, Employee shall devote Employee&#146;s best efforts, attention and
energies to the performance of Employee&#146;s duties as an employee of Axogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2&#8195;<U>Code of Conduct; Conflicts of Interest</U>.
Employee agrees to adhere to Axogen&#146;s Code of Business Conduct and Ethics, including but not limited to the provisions regarding Conflicts of Interest, as defined therein. Employee will not engage in any activity or have any outside interest
that could interfere with the satisfactory performance of Employee&#146;s duties or be detrimental to Axogen or be engaged in any other occupation or activity that conflicts with Employee&#146;s obligations to Axogen. Employee agrees to promptly
notify Axogen of any potential conflict of interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3.&#8195;<U>Agreements with Prior Employers</U>. Employee has not signed any <FONT
STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> or other agreement that Employee has not disclosed to Axogen that prohibits or restricts Employee from being employed by Axogen, fully
performing Employee&#146;s duties or fully providing services to or on behalf of Axogen during Employee&#146;s employment or assigning works and ideas to Axogen (&#147;<U>Prior <FONT STYLE="white-space:nowrap">Non-Compete</FONT>
Agreement</U>&#148;). Employee has not and will not disclose to Axogen or use for Axogen&#146;s benefit any information that to Employee&#146;s knowledge is proprietary or confidential to any of Employee&#146;s prior employers without proper consent
from the prior employer. If Employee has signed a Prior <FONT STYLE="white-space:nowrap">Non-Compete</FONT> Agreement with a prior employer, Employee has provided a copy of such agreement to Axogen&#146;s Human Resources Department under separate
cover. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4&#8195;<U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment</U>. Employee acknowledges that this IP and NCNS Agreement
does not obligate Employee to remain employed by Axogen nor does it confer upon Employee the right to continued employment by Axogen. Employee and Axogen each have the right to terminate the employment relationship at any time, for any reason or no
reason, with or without notice and with or without cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 &#8195;<U>Theft of Trade Secrets</U>. Employee acknowledges that Employee
is aware that a theft of trade secrets of an employer by an employee is an offense under federal law and the state laws of Florida and is prohibited by this IP and NCNS Agreement. Employee further acknowledges that such theft of trade secrets
constitutes a (i)&nbsp;criminal violation of Florida Statute 812.081, punishable as a third-degree felony under Florida Statute 775.082, conviction for which carries a term of imprisonment not exceeding five (5)&nbsp;years and (ii)&nbsp;a violation
of the federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Defend Trade Secrets Act and similar California and Nevada statutes. Employee
acknowledges AXOGEN will vigorously prosecute its rights under federal law and the state laws for any violation arising out of a breach by Employee of any of the material terms of this IP and NCNS Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6&#8195;<U>Advice of Counsel</U>. Employee acknowledges and agrees that Employee has read and understands the terms set forth in this IP and
NCNS Agreement and has been given a reasonable opportunity to consult with an attorney of their choosing prior to execution of IP and NCNS Agreement and has either done so, or knowingly declined to do so. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>MISCELLANEOUS</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1.&#8195;<U>Inside Information</U>. Employee hereby acknowledges that Employee is aware (and that Employee&#146;s representatives who are
apprised of this matter have been advised) that the United States securities laws prohibit Employee and any person or entity that has received material <FONT STYLE="white-space:nowrap">non-public</FONT> information about Axogen from Employee
(&#147;<U>Inside Information</U>&#148;) from purchasing or selling securities of Axogen or from communicating such information to any person under circumstances under which such other person may purchase or sell securities of Axogen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2&#8195;<U>Essence of the Agreement</U>. The restrictive covenants set forth in Sections <FONT STYLE="white-space:nowrap">2-4</FONT> are the
essence of this IP and NCNS Agreement and they shall be construed as agreements independent of (i)&nbsp;any other agreements, or (ii)&nbsp;any other provision in this IP and NCNS Agreement. Axogen shall not be barred from enforcing the restrictive
covenants set forth in Sections <FONT STYLE="white-space:nowrap">2-4</FONT> by reason of any breach of (i)&nbsp;any other part of this IP and NCNS Agreement, or (ii)&nbsp;any other agreement with Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3.&#8195;<U>Entire Agreement; Prior Agreements</U>. This IP and NCNS Agreement including its Schedules sets forth the entire agreement
between the Parties as it relates to the subject matter of this IP and NCNS Agreement; this IP and NCNS Agreement supersedes and replaces prior agreements between Employee and Axogen with respect to the subject matter addressed in the IP and NCNS
Agreement (except that any other confidentiality, intellectual property, or restrictive covenant agreement entered into between the parties shall be independently enforceable without regard to this IP and NCNS Agreement). The provisions of this IP
and NCNS Agreement shall not be amended, supplemented, waived or changed orally; any such alteration shall only be valid through a written amendment to this IP and NCNS Agreement signed by both Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4&#8195;<U>Severability</U>. This IP and NCNS Agreement shall be enforceable to the fullest extent allowed by law. In the event that a court
holds any provision of this IP and NCNS Agreement to be invalid or unenforceable, the Parties agrees that, if allowed by law, that provision shall be deemed severable from the remainder of this IP and NCNS Agreement, and the remaining provisions
contained in this IP and NCNS Agreement shall be construed to preserve the intent and purposes of this IP and NCNS Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5.&#8195;<U>Assignment</U>. This IP and NCNS Agreement shall be binding upon and inure to the benefit of the parties, their successors and
assigns. This IP and NCNS Agreement may not be assigned by Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6.&#8195;<U>Injunctive Relief</U>. Employee acknowledges that
because of the potential difficulty of measuring economic losses to Axogen as a result of a material breach or threatened material breach of any of the covenants in this IP and NCNS Agreement, and because of the immediate and irreparable damage that
may be caused to Axogen and for which monetary damages may not be a sufficient remedy and which harm may not be fully or adequately compensated by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recovery of damages alone, the Parties agree that, in addition to all other remedies or
damages that may be available to Axogen hereunder and at law or in equity, in the event of a material breach or a threatened material breach by Employee of any covenants in this IP and NCNS Agreement, Axogen shall be entitled to seek specific
performance and injunctions restraining such material breach without the posting of bond or other security from a federal or state court of competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7.&#8195;<U>Disputes and Litigation</U>. In the event of any dispute or litigation between or among the Parties with respect to this IP and
NCNS Agreement, the prevailing party shall be entitled to its costs and expenses, including reasonable attorneys&#146; fees and costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8.&#8195;<U>Governing Law</U>. This IP and NCNS Agreement and all transactions contemplated by this Agreement or the attached Schedules and
Exhibits shall be governed by, and construed and enforced in accordance with, the laws of the state in which Employee is most recently continually employed by AXOGEN for a thirty (30)&nbsp;day period, provided that until Employee has been employed
by AXOGEN for less than thirty (30)&nbsp;days, the law of the State of California shall be deemed to apply to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9.&#8195;<U>Counterparts; Transmission</U>. This IP and NCNS Agreement may be executed in one or more counterparts, each of which shall be
considered one and the same document. This IP and NCNS Agreement may be executed by facsimile or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10&#8195;<U>Preparation of Agreement</U>. This IP and NCNS Agreement shall not be construed more strongly against any party regardless of
who is responsible for its preparation. The Parties acknowledge that each party contributed to its negotiations and is equally responsible for its preparation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>[Signature Page Follows] </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Parties have caused this IP and NCNS Agreement to be
executed as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AXOGEN CORPORATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP><B>EMPLOYEE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Began</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Dale</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Marc&nbsp;Began</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Michael&nbsp;Dale</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, General Counsel and Chief Compliance Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Competing Organizations </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amniox
Medical Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applied Biologics Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Baxter International,
Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Checkpoint Surgical Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Guangzhou Zhongda Medical
(China) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Integra LifeSciences Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Medovent GmbH </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MiMedx Group Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neuraptive Therapeutics </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Polyganics B.V. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stryker Corporation </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vivex Biomedical Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tulavi Therapeutics, Inc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioCircuit Technologies, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Execution&nbsp;Version </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>List of Prior Intellectual Property </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d831362dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AXOGEN, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERFORMANCE-BASED RESTRICTED STOCK UNITS NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDUCEMENT AWARD </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Name of Grantee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Michael Dale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Notice evidences the award of performance-based restricted stock units (each, a &#147;<B><I>PSU</I></B>&#148; and
collectively, the &#147;<B><I>PSUs</I></B>&#148;) of Axogen, Inc., a Minnesota corporation (the &#147;<B><I>Company</I></B>&#148; or &#147;<B><I>Axogen</I></B>&#148;), that have been granted to and conditioned upon your agreement to the terms of the
attached Restricted Stock Units Agreement (the &#147;<B><I>Agreement</I></B>&#148;). The award of PSUs (the &#147;<B><I>Award</I></B>&#148;) is intended as a material inducement to you becoming an Employee and this award is intended to qualify as an
employment inducement grant under NASDAQ Listing Rule 5635(c)(4) and the official guidance thereunder. This Notice constitutes part of and is subject to the terms and provisions of the Agreement, which is incorporated by reference herein.&nbsp;Each
PSU is equivalent in value to one share of the Company&#146;s Common Stock and represents the Company&#146;s commitment to issue one share of the Company&#146;s Common Stock at a future date, subject to the terms of the Agreement.&nbsp;The PSUs are
credited to a separate account maintained for you on the books and records of the Company (the &#147;<B><I>Account</I></B>&#148;).&nbsp;All amounts credited to the Account will continue for all purposes to be part of the general assets of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Grant Date</U>: August&nbsp;9, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Performance Period</U>: Set forth on <U>Exhibit A</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Target Number of PSUs</U>: 450,000 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Performance-Based
PSUs</U>: The Target Number of PSUs stated above reflects the target number of PSUs that may vest pursuant to this Notice and the Agreement. The number of PSUs ultimately paid out to you will range from 0% to 200% of the Target Number of PSUs as
determined (i)&nbsp;by the formulas and terms contained on the attached <U>Exhibit A</U> and (ii)&nbsp;based upon the Company&#146;s achievement of certain performance goals during the applicable performance measurement period described below under
&#147;Performance-Based Vesting Schedule&#148; occurring during the Performance Period (the &#147;Performance Goals&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Performance-Based Vesting
Schedule</U>: All of the PSUs are nonvested and forfeitable as of the Grant Date. the Target Number of PSUs will be eligible to vest with respect to the Performance Period in accordance with the formulas and terms set forth on <U>Exhibit A</U>,
(i)&nbsp;subject to the achievement of the Performance Goals as set forth on <U>Exhibit A</U> and as determined by the Committee in its sole discretion and (ii)&nbsp;and provided that your Service (as defined in the Agreement) is continuous from the
Grant Date through the Certification Date, except as otherwise set forth on <U>Exhibit A</U> or in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Certification
Date</I></B>&#148; means the date on which the Committee certifies whether the Performance Goals for the full Performance Period have been met. The Certification Date with respect to the Performance Period as a whole will be no earlier than February
22<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> and no later than March 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the calendar year in which the Performance Period ends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Vesting Upon Termination of Service</U>: The following shall apply if your Service terminates during the
Performance Period: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the termination of your Service during the Performance Period for any reason other than due to your
Qualified Retirement that satisfies the requirements of Section&nbsp;4 of the Agreement, none of the Target Number of PSUs will be eligible to vest during the Performance Period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination of your Service during the Performance Period due to a Qualified Retirement that satisfies the
requirements of Section&nbsp;4 of the Agreement, the PSUs will be subject to the terms of Section&nbsp;4 of the Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
you hereby agree that, notwithstanding the terms of any employment agreement, employment offer letter, severance agreement or other severance arrangements between you and the Company or any of its Affiliates (each, a &#147;<U>Severance
Arrangement</U>&#148;), the PSUs shall not be subject to any additional acceleration of vesting pursuant to the terms of any Severance Arrangement or any subsequent severance plan or arrangement adopted by or implemented by the Company or any of its
Affiliates or any of their successors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Vesting Upon a Change in Control</U>: Notwithstanding anything to the contrary in this Notice or the Agreement,
if you remain in continuous Service until the closing of a Change in Control, the Target Number of PSUs eligible to vest during the Performance Period will vest based on actual performance as determined in accordance with <U>Exhibit A</U>, effective
as of immediately prior to the closing of the Change in Control. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Lindsey Peterson</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8/9/2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Axogen, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I acknowledge that I have carefully read the Agreement.&nbsp;I agree to be bound by all of the provisions set forth in the Agreement.&nbsp;I also consent to
electronic delivery of all notices or other information with respect to the PSUs or the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Michael Dale</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">8/9/2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature of Grantee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AXOGEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERFORMANCE-BASED RESTRICTED STOCK UNITS AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDUCEMENT AWARD </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Terminology</U>. Unless otherwise provided in this Agreement, capitalized terms used herein are defined in the Glossary at the end
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Vesting</U>. All of the PSUs are nonvested and forfeitable as of the Grant Date.&nbsp;The PSUs will become
vested and nonforfeitable in accordance with the vesting terms and conditions set forth in the Notice and <U>Exhibit A</U>.&nbsp;Except for the circumstances, if any, described in the Notice, or as otherwise provided in Section&nbsp;4 below, none of
the PSUs will become vested and nonforfeitable after your Service ceases. Any PSUs that do not satisfy the Performance Goals during the Performance Period, unless forfeited earlier, will be forfeited immediately upon the Certification Date for the
full Performance Period upon which the Committee determines that such Performance Goals have not been achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Termination
of Service</U>. Except as otherwise provided in Section&nbsp;4 below, or as otherwise provided in the Notice, if your Service with the Company ceases for any reason, all PSUs that are not then vested and nonforfeitable will be forfeited to the
Company immediately and automatically upon such cessation without payment of any consideration therefor and you will have no further right, title or interest in or to such PSUs or the underlying shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Qualified Retirement</U>. If your title with the Company as of the Grant Date of the PSUs is Vice President or above, in the event
your Service with the Company ceases by reason of a Qualified Retirement during the Performance Period, and such Qualified Retirement occurs on a date that is at least twelve (12)&nbsp;months following the Grant Date, (i)&nbsp;if you have at least
ten (10)&nbsp;years of continuous Service but less than fifteen (15)&nbsp;years of continuous Service as of the date of your Qualified Retirement, then the Target Number of PSUs will continue to be eligible to become vested and nonforfeitable based
on actual performance in accordance with the vesting terms and conditions set forth in the Notice and <U>Exhibit A</U>; provided, that the Target Number of PSUs that are eligible to vest shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT>
based on the number of days of your Service in the Performance Period (and for the avoidance of doubt, any <FONT STYLE="white-space:nowrap">pro-rated</FONT> amount for a partial Calendar Year during which the Qualified Retirement occurs will be
eligible to vest based on actual performance for such Calendar Year) and (ii)&nbsp;if you have at least fifteen (15)&nbsp;years of continuous Services as of the date of your Qualified Retirement, then the full Target Number of PSUs will continue to
be eligible to become vested and nonforfeitable during the Performance Period based on actual performance in accordance with the vesting schedule set forth in the Notice. Notwithstanding the foregoing, all vesting shall cease and any remaining PSUs
that are not then vested and nonforfeitable will be forfeited to the Company immediately and automatically upon your death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Restrictions on Transfer</U>. Neither this Agreement nor any of the PSUs may be assigned, transferred, pledged, hypothecated or
disposed of in any way, whether by operation of law or otherwise, and the PSUs shall not be subject to execution, attachment or similar process.&nbsp;All rights with respect to this Agreement and the PSUs shall be exercisable during your lifetime
only by you or your guardian or legal representative.&nbsp;Notwithstanding the foregoing, the PSUs, to the extent outstanding, may be transferred upon your death by last will and testament or under the laws of descent and distribution.
Notwithstanding the foregoing, except as otherwise restricted by applicable law, the Committee may, but need not, permit the PSUs to be transferred to one of your Family Members (as defined below) as a gift or pursuant to a domestic relations order
in settlement of marital property rights. The Committee shall not permit any transfer of the PSUs for value. For purposes of this Section&nbsp;5, &#147;<B><I>Family Member</I></B>&#148; means any child, stepchild, grandchild, parent, stepparent,
grandparent, spouse, former spouse, sibling, niece, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nephew, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including adoptive relationships, any person sharing your household (other than a tenant or employee), a trust in which these persons have more than 50%
of the beneficial interest, a foundation in which these persons (or you) control the management of assets, and any other entity in which these persons (or you) own more than 50% of the voting interests. The following transactions are not prohibited
transfers for value: (i)&nbsp;a transfer under a domestic relations order in settlement of marital property rights; and (ii)&nbsp;a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or you) in exchange
for an interest in that entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Settlement of PSUs</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Manner of Settlement</U>. You are not required to make any monetary payment (other than applicable tax withholding, if required)
as a condition to settlement of the PSUs.&nbsp;The Company will issue to you, in settlement of your PSUs and subject to the provisions of Section&nbsp;7 below, the number of whole shares of Common Stock that equals the number of whole PSUs that
become vested, and such vested PSUs will terminate and cease to be outstanding upon such issuance of the shares.&nbsp;Upon issuance of such shares, the Company will determine the form of delivery (e.g., a stock certificate or electronic entry
evidencing such shares) and may deliver such shares on your behalf electronically to the Company&#146;s designated stock plan administrator or such other broker-dealer as the Company may choose at its sole discretion, within reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Timing of Settlement</U>. Your PSUs, to the extent vested, will be settled by the Company, via the issuance of Common Stock as
described herein, during the Calendar Year immediately following the end of the Performance Period, within the first ninety (90)&nbsp;days of such Calendar Year (the &#147;<B><I>Issuance Date</I></B>&#148;). In no event will you be permitted,
directly or indirectly, to designate the Issuance Date. However, if a scheduled Issuance Date falls on a Saturday, Sunday or federal holiday, such Issuance Date shall instead fall on the next following day that the principal executive offices of the
Company are open for business. Notwithstanding the foregoing, in the event that (i)&nbsp;you are subject to the Company&#146;s policy permitting officers and directors to sell shares only during certain &#147;window&#148; periods, in effect from
time to time or you are otherwise prohibited from selling shares of the Company&#146;s Common Stock in the public market and any shares covered by your PSUs are scheduled to be issued on a day (the &#147;<B><I>Original Distribution
Date</I></B>&#148;) that does not occur during an open &#147;window period&#148; applicable to you, as determined by the Company in accordance with such policy, or does not occur on a date when you are otherwise permitted to sell shares of the
Company&#146;s Common Stock in the open market, and (ii)&nbsp;the Company elects not to satisfy its tax withholding obligations by withholding shares from your distribution, then, solely to the extent permitted by Section&nbsp;409A (as defined
below), such shares shall not be issued and delivered on such Original Distribution Date and shall instead be issued and delivered on the first business day of the next occurring open &#147;window period&#148; applicable to you pursuant to such
policy (regardless of whether you are still providing continuous services at such time) or the next business day when you are not prohibited from selling shares of the Company&#146;s Common Stock in the open market, but in no event later than
December 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the calendar year in which the Issuance Date occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>Tax Withholding</U>. On or before the time you receive a distribution of the shares subject to your PSUs, or at any time
thereafter as requested by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and
foreign tax withholding obligations of the Company or any Affiliate which arise in connection with your PSUs (the &#147;<B><I>Withholding Taxes</I></B>&#148;).&nbsp;Additionally, the Company may, in its sole discretion, satisfy all or any portion of
the Withholding Taxes obligation relating to your PSUs by any of the following means or by a combination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of such means: (i)&nbsp;withholding from any compensation otherwise payable to you by the Company; (ii)&nbsp;causing you to tender a cash payment; (iii)&nbsp;permitting you to enter into a
&#147;same day sale&#148; commitment with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a &#147;<B><I>FINRA Dealer</I></B>&#148;) whereby you irrevocably elect to sell a portion of the shares to be delivered under
the Agreement to satisfy the Withholding Taxes and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Withholding Taxes directly to the Company; or (iv)&nbsp;withholding shares of Common Stock from the
shares of Common Stock issued or otherwise issuable to you in connection with the PSUs with a Fair Market Value (measured as of the date shares of Common Stock are issued to you pursuant to Section&nbsp;6 of this Agreement) equal to the amount of
such Withholding Taxes; provided, however, that the number of such shares of Common Stock so withheld shall not exceed, by more than the Fair Market Value of one share of Common Stock, the amount necessary to satisfy the Company&#146;s required tax
withholding obligations using the minimum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income.&nbsp;Unless the tax withholding obligations of the
Company and/or any Affiliate are satisfied, the Company shall have no obligation to deliver to you any Common Stock.&nbsp;In the event the Company&#146;s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined
after the delivery of Common Stock to you that the amount of the Company&#146;s withholding obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to
withhold the proper amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Adjustments for Corporate Transactions and Other Events</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Mandatory Adjustments</U>. In the event of a merger, consolidation, stock rights offering, statutory share exchange or similar
event affecting Axogen (each, a &#147;<B><I>Corporate Event</I></B>&#148;) or a stock dividend, stock split, reverse stock split, separation, spinoff, reorganization, extraordinary dividend of cash or other property, share combination or
subdivision, or recapitalization or similar event affecting the capital structure of Axogen (each, a &#147;<B><I>Share Change</I></B>&#148;) that occurs at any time after the Grant Date, the Committee shall make equitable and appropriate
substitutions or proportionate adjustments to (i)&nbsp;the aggregate number and kind of shares of Common Stock or other securities on which the Award is granted, (ii)&nbsp;the number of shares of Common Stock or other securities covered by the Award
and other relevant terms of each outstanding Award, and (iii)&nbsp;all other numerical limitations relating to the Awards; <I>provided</I>, <I>however</I>, that any fractional shares resulting from any such adjustment shall be eliminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Discretionary Adjustments</U>. In the case of Corporate Events, the Committee may make such other adjustments to the Award as it
determines to be appropriate and desirable, which adjustments may include, without limitation, (i)&nbsp;the cancellation of the Award in exchange for payments of cash, securities or other property or a combination thereof having an aggregate value
equal to the value of the Award, as determined by the Committee in its sole discretion, (ii)&nbsp;the substitution of securities or other property (including, without limitation, cash or other securities of Axogen and securities of entities other
than Axogen) for the shares of Common Stock subject to the Award, and (iii)&nbsp;the substitution of equivalent awards, as determined in the sole discretion of the Committee, of the surviving or successor entity or a parent thereof
(&#147;<B><I>Substitute Awards</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Adjustments to Performance Goals</U>. The Committee may, in its discretion,
adjust the Performance Goal applicable to the Award to reflect any unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> events and other extraordinary items, impact of charges for restructurings, discontinued operations and the
cumulative effects of accounting or tax changes, each as defined by generally accepted accounting principles or as identified in Axogen&#146;s consolidated financial statements, notes to the consolidated financial statements, management&#146;s
discussion and analysis or other Axogen filings with the Securities and Exchange </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Commission. If the Committee determines that a change in the business, operations, corporate structure or capital structure of Axogen or the applicable subsidiary, business segment or other
operational unit of Axogen or any such entity or segment, or the manner in which any of the foregoing conducts its business, or other events or circumstances, render the Performance Goals to be unsuitable, the Committee may modify such Performance
Goals or the related minimum acceptable level of achievement, in whole or in part, as the Committee deems appropriate and equitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<U>Statutory Requirements Affecting Adjustments</U>. Notwithstanding the foregoing: (i)&nbsp;any adjustments made pursuant to this
Section&nbsp;8 to the Award that are considered &#147;deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code shall be made in compliance with the requirements of Section&nbsp;409A of the Code; (ii)&nbsp;any adjustments made
pursuant to this Section&nbsp;8 that are not considered &#147;deferred compensation&#148; subject to Section&nbsp;409A of the Code shall be made in such a manner as to ensure that after such adjustment, the Award either (A)&nbsp;continues not to be
subject to Section&nbsp;409A of the Code or (B)&nbsp;complies with the requirements of Section&nbsp;409A of the Code; and (iii)&nbsp;in any event, the Committee shall not have the authority to make any adjustments pursuant to this Section&nbsp;8 to
the extent the existence of such authority would cause the Award that is not intended to be subject to Section&nbsp;409A of the Code at the date of grant to be subject thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<U>Dissolution or Liquidation</U><I>.</I> Unless the Committee determines otherwise, the Award shall terminate upon the dissolution
or liquidation of Axogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<U>Non</U><U><FONT STYLE="white-space:nowrap">-Guarantee</FONT> of Employment or Service
Relationship</U>. Nothing in this Agreement shall alter your <FONT STYLE="white-space:nowrap">at-will</FONT> or other employment status or other service relationship with the Company, nor be construed as a contract of employment or service
relationship between the Company and you, or as a contractual right of you to continue in the employ of, or in a service relationship with, the Company for any period of time, or as a limitation of the right of the Company to discharge you at any
time with or without cause or notice and whether or not such discharge results in the forfeiture of any nonvested and forfeitable PSUs or any other adverse effect on your interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Rights as Stockholder</U>. You shall not have any of the rights of a stockholder with respect to any shares of Common Stock that
may be issued in settlement of the PSUs until such shares of Common Stock have been issued to you.&nbsp;No adjustment shall be made for dividends, distributions, or other rights for which the record date is prior to the date such shares are issued,
except as provided in Section&nbsp;8 of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>The Company&#146;s Rights</U>. The existence of the PSUs shall not
affect in any way the right or power of the Company or its stockholders to make or authorize any or all adjustments, recapitalizations, reorganizations, or other changes in the Company&#146;s capital structure or its business, or any merger or
consolidation of the Company, or any issue of bonds, debentures, preferred or other stocks with preference ahead of or convertible into, or otherwise affecting the Common Stock or the rights thereof, or the dissolution or liquidation of the Company,
or any sale or transfer of all or any part of the Company&#146;s assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Restrictions on Issuance of Shares</U>. The issuance of shares of Common Stock upon settlement of the PSUs shall be subject to
and in compliance with all applicable requirements of federal, state, or foreign law with respect to such securities.&nbsp;No shares of Common Stock may be issued hereunder if the issuance of such shares would constitute a violation of any
applicable federal, state, or foreign securities laws or other law or regulations or the requirements of any stock exchange or market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
system upon which the Common Stock may then be listed.&nbsp;The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company&#146;s
legal counsel to be necessary to the lawful issuance of any shares subject to the PSUs shall relieve the Company of any liability in respect of the failure to issue such shares as to which such requisite authority shall not have been
obtained.&nbsp;As a condition to the settlement of the PSUs, the Company may require you to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation, and to make any representation
or warranty with respect thereto as may be requested by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Restrictive Covenants</U>. You hereby agree to the
following restrictive covenants as consideration of the grant of the PSUs: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;You hereby agree and acknowledge that the grant of
the PSUs is conditioned upon your continued compliance with any and all confidentiality, <FONT STYLE="white-space:nowrap">non-compete</FONT> and/or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> covenants and restrictions contained in any
separate agreement between you and the Company, and if you breach any of such covenants or restrictions, upon written notice delivered to you: (i)&nbsp;the entirety of the Company&#146;s obligations under this Agreement shall terminate in their
entirety, (ii)&nbsp;all PSUs that are not then vested and nonforfeitable will be forfeited to the Company immediately and automatically, and (iii)&nbsp;you shall have no further rights or privileges under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<U>Notices</U>. All notices and other communications made or given pursuant to this Agreement shall be given in writing and shall be
deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5)&nbsp;days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company, or in
the case of notices delivered to the Company by you, addressed to the Committee, care of the Company for the attention of its Secretary at its principal executive office or, in either case, if the receiving party consents in advance, transmitted and
received via telecopy or via such other electronic transmission mechanism as may be available to the parties.&nbsp;Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to this award of PSUs
by electronic means or to request your consent to accept this award of PSUs by electronic means.&nbsp;You hereby consent to receive such documents by electronic delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<U>Entire Agreement</U>. This Agreement, together with the relevant Notice, contain the entire agreement between the parties with
respect to the PSUs granted hereunder.&nbsp;Any oral or written agreements, representations, warranties, written inducements, or other communications made prior to the execution of this Agreement with respect to the PSUs granted hereunder shall be
void and ineffective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#8195;<U>Amendment</U>. This Agreement may be amended from time to time by the Committee in
its discretion; <U>provided</U>, <U>however</U>, that this Agreement may not be modified in a manner that would have a materially adverse effect on the PSUs as determined in the discretion of the Committee, except as provided in a written document
signed by each of the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&#8195;<U>Change in Control Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Termination of Award</U>. Notwithstanding the provisions of <U>Section</U><U></U><U>&nbsp;17(b)</U>, in the event that any
transaction resulting in a Change in Control occurs, the Award, if outstanding at such time, will terminate upon the effective time of such Change in Control unless provision is made in connection with the transaction for the continuation or
assumption of the Award by, or for the issuance therefor of a Substitute Award of, the surviving or successor entity or a parent thereof. Solely with respect to if the Award will terminate as a result of the immediately preceding sentence, the
vesting and earnings of the Award shall be as provided for in <U>Exhibit A</U> on the occurrence of a Change in Control during the Performance Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Continuation, Assumption or Substitution of Awards</U>. The Committee may specify, on or after the Grant Date, the consequences
of your termination of Service that occurs coincident with or following the occurrence of a Change in Control, if a Change in Control occurs under which provision is made in connection with the transaction for the continuation or assumption of
outstanding Awards by, or for the issuance therefor of Substitute Awards of, the surviving or successor entity or a parent thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Other Permitted Actions</U>. In the event that any transaction resulting in a Change in Control occurs, the Committee may take
any of the actions set forth in <U>Section</U><U></U><U>&nbsp;8</U> with respect to the Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&#8195;<U>409A Savings Clause</U>. This
Agreement and the PSUs granted hereunder are intended to be exempt from or comply with the requirements of Section&nbsp;409A of the Code and the regulations and IRS guidance promulgated thereunder
(&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;).&nbsp;In administering this Agreement, the Company shall interpret this Agreement in a manner consistent with Section&nbsp;409A. To the extent necessary to comply with
Section&nbsp;409A, if you are a &#147;Specified Employee&#148; (within the meaning set forth Section&nbsp;409A(a)(2)(B)(i) of the Code) as of the date of your separation from service (within the meaning of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)),</FONT> then the issuance of any shares that would otherwise be made upon the date of the separation from service or within the first six (6)&nbsp;months thereafter will not be made on the
originally scheduled date(s) and will instead be issued in a lump sum on the date that is six (6)&nbsp;months and one day after the date of the separation from service, but if and only if such delay in the issuance of the shares is necessary to
avoid the imposition of additional taxation on you in respect of the shares under Section&nbsp;409A.&nbsp;Each installment of shares that vests is intended to constitute a &#147;separate payment&#148; for purposes of Section&nbsp;409A and Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).&nbsp;For</FONT> purposes of Section&nbsp;409A, the payment of dividend equivalents under this Agreement, if any, shall be construed as earnings and the time and form of payment
of such dividend equivalents shall be treated separately from the time and form of payment of the underlying PSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&#8195;<U>No
Obligation to Minimize Taxes</U>.&nbsp;The Company has no duty or obligation to minimize the tax consequences to you of this award of PSUs and shall not be liable to you for any adverse tax consequences to you arising in connection with this
award.&nbsp;You are hereby advised to consult with your own personal tax, financial and/or legal advisors regarding the tax consequences of this award and by signing the Notice, you have agreed that you have done so or knowingly and voluntarily
declined to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&#8195;<U>No Funding</U>.&nbsp;This Agreement constitutes an unfunded and unsecured promise by the Company to issue
shares of Common Stock in the future in accordance with its terms.&nbsp;You have the status of a general unsecured creditor of the Company as a result of receiving the grant of PSUs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&#8195;<U>Effect on Other Employee Benefit Plans</U>.&nbsp;The value of the PSUs subject
to this Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise
expressly provides.&nbsp;The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#146;s or any Affiliate&#146;s employee benefit plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&#8195;<U>Governing Law</U>.&nbsp;The validity, construction and effect of this Agreement, and of any determinations or decisions made by
the Committee relating to this Agreement, and the rights of any and all persons having or claiming to have any interest under this Agreement, shall be determined exclusively in accordance with the laws of the State of Minnesota, without regard to
its provisions concerning the applicability of laws of other jurisdictions.&nbsp;As a condition of this Agreement, you agree that you will not bring any action arising under, as a result of, pursuant to or relating to, this Agreement in any court
other than a federal or state court in the districts which include New Jersey, and you hereby agree and submit to the personal jurisdiction of any federal court located in the district which includes New Jersey or any state court in the district
which includes New Jersey.&nbsp;You further agree that you will not deny or attempt to defeat such personal jurisdiction or object to venue by motion or other request for leave from any such court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.&#8195;<U>Resolution of Disputes</U>.&nbsp;Any dispute or disagreement which shall arise under, or as a result of, or pursuant to or
relating to, this Agreement shall be determined by the Committee in good faith in its absolute and uncontrolled discretion, and any such determination or any other determination by the Committee under or pursuant to this Agreement and any
interpretation by the Committee of the terms of this Agreement, will be final, binding and conclusive on all persons affected thereby.&nbsp;You agree that before you may bring any legal action arising under, as a result of, pursuant to or relating
to, this Agreement you will first exhaust your administrative remedies before the Committee.&nbsp;You further agree that in the event that the Committee does not resolve any dispute or disagreement arising under, as a result of, pursuant to or
relating to, this Agreement to your satisfaction, no legal action may be commenced or maintained relating to this Agreement more than twenty-four (24)&nbsp;months after the Committee&#146;s decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.&#8195;<U>Headings</U>.&nbsp;The headings in this Agreement are for reference purposes only and shall not affect the meaning or
interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.&#8195;<U>Electronic Delivery of Documents</U>.&nbsp;By your signing the Notice, you
(i)&nbsp;consent to the electronic delivery of this Agreement, all information with respect to the PSUs, and any reports of the Company provided generally to the Company&#146;s stockholders; (ii)&nbsp;acknowledge that you may receive from the
Company a paper copy of any documents delivered electronically at no cost to you by contacting the Company by telephone or in writing; (iii)&nbsp;further acknowledge that you may revoke your consent to the electronic delivery of documents at any
time by notifying the Company of such revoked consent by telephone, postal service or electronic mail; and (iv)&nbsp;further acknowledge that you understand that you are not required to consent to electronic delivery of documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.&#8195;<U>No Future Entitlement</U>.&nbsp;By your signing the Notice, you acknowledge and agree that:&nbsp;(i)&nbsp;the grant of a
restricted stock unit award is a <FONT STYLE="white-space:nowrap">one-time</FONT> benefit which does not create any contractual or other right to receive future grants of restricted stock units, or compensation in lieu of restricted stock units,
even if restricted stock units have been granted repeatedly in the past; (ii)&nbsp;all determinations with respect to any such future grants and the terms thereof will be at the sole discretion of the Committee; (iii)&nbsp;the value of the
restricted stock units is an extraordinary item of compensation which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is outside the scope of your employment contract, if any; (iv)&nbsp;the value of the restricted stock units is not part of normal or expected compensation or salary for any purpose, including,
but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments or similar payments, or bonuses, long-service awards, pension or retirement benefits; (v)&nbsp;the vesting of the restricted stock units
ceases upon termination of Service with the Company or transfer of employment from the Company, or other cessation of eligibility for any reason, except as may otherwise be explicitly provided in this Agreement; (vi)&nbsp;the Company does not
guarantee any future value of the restricted stock units; and (vii)&nbsp;no claim or entitlement to compensation or damages arises if the restricted stock units decrease or do not increase in value and you irrevocably release the Company from any
such claim that does arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.&#8195;<U>Personal Data</U>.&nbsp;For purposes of the implementation, administration and management of the
restricted stock units or the effectuation of any acquisition, equity or debt financing, joint venture, merger, reorganization, consolidation, recapitalization, business combination, liquidation, dissolution, share exchange, sale of stock, sale of
material assets or other similar corporate transaction involving the Company (a &#147;<B><I>Corporate Transaction</I></B>&#148;), you consent, by execution of the Notice, to the collection, receipt, use, retention and transfer, in electronic or
other form, of your personal data by and among the Company and its third party vendors or any potential party to a potential Corporate Transaction.&nbsp;You understand that personal data (including but not limited to, name, home address, telephone
number, employee number, employment status, social security number, tax identification number, date of birth, nationality, job and payroll location, data for tax withholding purposes and shares awarded, cancelled, vested and unvested) may be
transferred to third parties assisting in the implementation, administration and management of the restricted stock units or the effectuation of a Corporate Transaction and you expressly authorize such transfer as well as the retention, use, and the
subsequent transfer of the data by the recipient(s).&nbsp;You understand that these recipients may be located in your country or elsewhere, and that the recipient&#146;s country may have different data privacy laws and protections than your
country.&nbsp;You understand that data will be held only as long as is necessary to implement, administer and manage the restricted stock units or effect a Corporate Transaction.&nbsp;You understand that you may, at any time, request a list with the
names and addresses of any potential recipients of the personal data, view data, request additional information about the storage and processing of data, require any necessary amendments to data or refuse or withdraw the consents herein, in any case
without cost, by contacting in writing the Company&#146;s Secretary.&nbsp;You understand, however, that refusing or withdrawing your consent may affect your ability to accept a restricted stock unit award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">{<I>Glossary begins on next page}</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GLOSSARY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;&#147;<B><I>Affiliate</I></B><I>&#148;</I> means any entity, whether now or hereafter existing, which controls, is controlled by, or
is under common control with, Axogen or any successor to Axogen. For this purpose, &#147;control&#148; (including the correlative meanings of the terms &#147;controlled by&#148; and &#147;under common control with&#148;) shall mean ownership,
directly or indirectly, of 50% or more of the total combined voting power of all classes of voting securities issued by such entity, or the possession, directly or indirectly, of the power to direct the management and policies of such entity, by
contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;&#147;<B><I>Agreement</I></B>&#148; means this document, as amended from time to time, together with the
Notice which is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;&#147;<B><I>Board</I></B>&#148; means the Board of Directors of Axogen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;&#147;<B><I>Cause</I></B>&#148; means as such term is defined in the Executive Employment Agreement between the Company and you
dated effective as of August&nbsp;9, 2024 as may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;&#147;<B><I>Change in Control</I></B>&#148;
means the first of the following to occur: (i)&nbsp;a Change in Ownership of Axogen, (ii)&nbsp;a Change in Effective Control of Axogen, or (iii)&nbsp;a Change in the Ownership of Assets of Axogen, as described herein and construed in accordance with
Code section 409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">a.&#8195;A &#147;Change in Ownership of Axogen&#148; shall occur on the date that any one Person acquires, or Persons
Acting as a Group acquire, ownership of the capital stock of Axogen that, together with the stock held by such Person or Group, constitutes more than 50% of the total fair market value or total voting power of the capital stock of Axogen. However,
if any one Person is, or Persons Acting as a Group are, considered to own more than 50%, on a fully diluted basis, of the total fair market value or total voting power of the capital stock of Axogen, the acquisition of additional stock by the same
Person or Persons Acting as a Group is not considered to cause a Change in Ownership of Axogen or to cause a Change in Effective Control of Axogen (as described below). An increase in the percentage of capital stock owned by any one Person, or
Persons Acting as a Group, as a result of a transaction in which Axogen acquires its stock in exchange for property will be treated as an acquisition of stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">b.&#8195;A &#147;Change in Effective Control of Axogen&#148; shall occur on the date either (A)&nbsp;a majority of members of Axogen&#146;s
Board is replaced during any <FONT STYLE="white-space:nowrap">12-month</FONT> period by Directors whose appointment or election is not endorsed by a majority of the members of Axogen&#146;s Board before the date of the appointment or election, or
(B)&nbsp;any one Person, or Persons Acting as a Group, acquires (or has acquired during the <FONT STYLE="white-space:nowrap">12-month</FONT> period ending on the date of the most recent acquisition by such Person or Persons) ownership of stock of
Axogen possessing 50% or more of the total voting power of the stock of Axogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">c.&#8195;A &#147;Change in the Ownership of Assets of
Axogen&#148; shall occur on the date that any one Person acquires, or Persons Acting as a Group acquire (or has or have acquired during the <FONT STYLE="white-space:nowrap">12-month</FONT> period ending on the date of the most recent acquisition by
such Person or Persons), assets from Axogen that have a total gross fair market value equal to or more than 51% of the total gross fair market value of all of the assets of Axogen immediately before such acquisition or acquisitions. For this
purpose, gross fair market value means the value of the assets of Axogen, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following rules of construction apply in interpreting the definition of Change in
Control: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A)&#8195;A &#147;<B><I>Person</I></B>&#148; means any individual, entity or group within the meaning of Section&nbsp;13(d)(3)
or 14(d)(2) of the Securities Exchange Act of 1934, as amended, other than employee benefit plans sponsored or maintained by Axogen and by entities controlled by Axogen or an underwriter, initial purchaser or placement agent temporarily holding the
capital stock of Axogen pursuant to a registered public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B)&#8195;Persons will be considered to be Persons Acting as a Group
(or Group) if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the corporation. If a Person owns stock in both corporations that enter into a merger,
consolidation, purchase or acquisition of stock, or similar transaction, such shareholder is considered to be acting as a Group with other shareholders only with respect to the ownership in that corporation before the transaction giving rise to the
change and not with respect to the ownership interest in the other corporation. Persons will not be considered to be acting as a Group solely because they purchase assets of the same corporation at the same time or purchase or own stock of the same
corporation at the same time, or as a result of the same public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(C)&#8195;A Change in Control shall not include a transfer to
a related person as described in Code section 409A or a public offering of capital stock of Axogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(D)&#8195;For purposes of the
definition of Change in Control, Section&nbsp;318(a) of the Code applies to determine stock ownership. Stock underlying a vested option is considered owned by the individual who holds the vested option (and the stock underlying an unvested option is
not considered owned by the individual who holds the unvested option). For purposes of the preceding sentence, however, if a vested option is exercisable for stock that is not substantially vested (as defined by Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.83-3(b)</FONT> and (j)), the stock underlying the option is not treated as owned by the individual who holds the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>&#147;</I><B><I>Code</I></B><I>&#148; </I>means the Internal Revenue Code of 1986, as amended from time to time, and any
successor thereto, the Treasury Regulations thereunder and other relevant interpretive guidance issued by the Internal Revenue Service or the Treasury Department. Reference to any specific section of the Code shall be deemed to include such
regulations and guidance, as well as any successor section, regulations and guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<I>&#147;</I><B><I>Committee</I></B><I>&#148;</I> means the Compensation Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<I>&#147;</I><B><I>Common Stock</I></B><I>&#148; </I>means shares of common stock of Axogen, par value $0.01 per share, and any
capital securities into which they are converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<I>&#147;</I><B><I>Director</I></B>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<I>&#147;</I><B><I>Fair Market Value</I></B>&#148; means, on a per share basis as of any date, unless otherwise determined by the
Committee: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">a.&#8195;if the principal market for the Common Stock (as determined by the Committee if the Common Stock is listed or
admitted to trading on more than one exchange or market) is a national securities exchange or an established securities market, the official closing price per share of Common Stock for the regular market session on that date on the principal
exchange or market on which the Common Stock is then listed or admitted to trading or, if no sale is reported for that date, on the last preceding day on which a sale was reported, all as reported by such source as the Committee may select; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">b.&#8195;if the principal market for the Common Stock is not a national securities exchange
or an established securities market, but the Common Stock is quoted by a national quotation system, the average of the highest bid and lowest asked prices for the Common Stock on that date as reported on a national quotation system or, if no prices
are reported for that date, on the last preceding day on which prices were reported, all as reported by such source as the Committee may select; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">c.&#8195;if the Common Stock is neither listed or admitted to trading on a national securities exchange or an established securities market,
nor quoted by a national quotation system, the value determined by the Committee in good faith by the reasonable application of a reasonable valuation method, which method may, but need not, include taking into account an appraisal of the fair
market value of the Common Stock conducted by a nationally recognized appraisal firm selected by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
preceding, for foreign, federal, state and local income tax reporting purposes and for such other purposes as the Committee deems appropriate, the Fair Market Value shall be determined by the Committee in accordance with uniform and
nondiscriminatory standards adopted by it from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&#8195;&#147;<B><I>Grant Date</I></B>&#148; means the effective date of a
grant of PSUs made to you as set forth in the relevant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&#8195;&#147;<B><I>Notice</I></B>&#148; means the statement, letter or
other written notification provided to you by the Company setting forth the terms of a grant of PSUs made to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&#8195;&#147;<B><I>PSU</I></B>&#148;&nbsp;means the Company&#146;s commitment to issue one share of Common Stock at a future date, subject
to the terms of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&#8195;&#147;<B><I>Qualified Retirement</I></B>&#148; means the termination of your Service after
attainment of age sixty (60)&nbsp;with at least ten (10)&nbsp;years of continuous Service, provided that: (i)&nbsp;as a Vice-President or above, if you elect to terminate your Service voluntarily, you have provided the Company with at least twelve
(12)&nbsp;months&#146; advance notice of your retirement date or such other term of advance notice as is determined by the Chief Human Resources Officer of the Company; (ii)&nbsp;as a Vice-President or above, if the Company elected to terminate your
Service, such termination is without Cause and (iii)&nbsp;during the three (3)&nbsp;years prior to the year in which such termination of Service occurs, you have maintained consistent historical performance reviews. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&#8195;&#147;<B>Service</B>&#148; means your employment, service as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director or
other service relationship with the Company and its Affiliates.&nbsp;Your Service will be considered to have ceased with the Company and its Affiliates if, immediately after a sale, merger, or other corporate transaction, the trade, business, or
entity with which you are employed or otherwise have a service relationship is not Axogen, Inc., or its successor or an Affiliate of Axogen, Inc. or its successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&#8195;&#147;<B><I>You</I></B>&#148; or &#147;<B><I>Your</I></B>&#148; means the recipient of the PSUs as reflected on the applicable
Notice.&nbsp;Whenever the word &#147;you&#148; or &#147;your&#148; is used in any provision of this Agreement under circumstances where the provision should logically be construed, as determined by the Committee, to apply to the estate, personal
representative, or beneficiary to whom the PSUs may be transferred by will or by the laws of descent and distribution, the words &#147;you&#148; and &#147;your&#148; shall be deemed to include such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">{<I>End of Agreement}</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Terms of Performance Restricted Stock Units </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Performance Vesting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Performance
Period and Allocation of Target Number of PSUs </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Performance Period is the three Calendar Year period beginning February 22, 2024 and ending
February&nbsp;22, 2027. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Calculation of Actual PSU Vesting </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Continued Service Through Performance Period </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you
remain in continuous Service through the end of the Performance Period, the actual number of PSUs that vest during the Performance Period will be calculated on the Certification Date at the end of the Performance Period and will equal: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Target Number of PSUs; <I>multiplied by</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(y)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payout Percentage. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Payout Percentage will be determined based on the Company&#146;s Closing Average Share Price during the Performance Period as follows, with linear
interpolation for Closing Average Share Price achievement in between performance levels: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[REDACTED] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Closing Average Share Price</I></B>&#148; means the average Share Price over the 30 trading days immediately preceding the end of the Performance
Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Share Price</I></B>&#148; means, with respect to a given trading day, the closing price of the Company&#146;s Common Stock for such
trading day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total number of PSUs that will vest will be rounded down to the nearest whole PSU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Service During Performance Period </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your
Service terminates during the Performance Period for any reason other than due to a Qualified Retirement, none of your PSUs shall vest and you shall forfeit your PSUs in their entirety. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your Service terminates during the Performance Period due to a Qualified Retirement, the PSUs will remain eligible to vest as set forth in Section&nbsp;4 of
the Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Occurrence of a Change in Control During Performance Period </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the closing of a Change in Control occurs during the Performance Period, subject to the terms of the Notice and your Service through the closing of such
Change in Control, you will be eligible to vest in the PSUs based on actual performance, effective as of the closing of the Change in Control. For </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes of calculating Closing Average Share Price and, accordingly, the Payout Percentage, the Closing Average Share Price will be calculated based on the price per share paid in respect of a
share of Common Stock in the Change in Control, with any contingent consideration, including contingent value rights, received by holders of shares of Common Stock valued as if the contingency was achieved in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>d831362dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AXOGEN, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERFORMANCE-BASED RESTRICTED STOCK UNITS NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDUCEMENT AWARD </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:11pt"><B>Name&nbsp;of&nbsp;Grantee:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Michael Dale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Notice evidences the award of performance-based restricted stock units (each, a &#147;<B><I>PSU</I></B>&#148; and
collectively, the &#147;<B><I>PSUs</I></B>&#148;) of Axogen, Inc., a Minnesota corporation (the &#147;<B><I>Company</I></B>&#148; or &#147;<B><I>Axogen</I></B>&#148;), that have been granted to you and conditioned upon your agreement to the terms of
the attached Restricted Stock Units Agreement (the &#147;<B><I>Agreement</I></B>&#148;). The award of PSUs (the &#147;<B><I>Award</I></B>&#148;) is intended as a material inducement to you becoming an Employee and this Award is intended to qualify
as an employment inducement grant under NASDAQ Listing Rule 5635(c)(4) and the official guidance thereunder. This Notice constitutes part of and is subject to the terms and provisions of the Agreement, which is incorporated by reference
herein.&nbsp;Each PSU is equivalent in value to one share of the Company&#146;s Common Stock and represents the Company&#146;s commitment to issue one share of the Company&#146;s Common Stock at a future date, subject to the terms of the
Agreement.&nbsp;The PSUs are credited to a separate account maintained for you on the books and records of the Company (the &#147;<B><I>Account</I></B>&#148;).&nbsp;All amounts credited to the Account will continue for all purposes to be part of the
general assets of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Grant Date</U>: August&nbsp;9, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Performance Period</U>:&#8195;Set forth on <U>Exhibit A</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Target Number of PSUs</U>: 150,000 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Performance-Based
PSUs</U>: The Target Number of PSUs stated above reflects the target number of PSUs that may vest pursuant to this Notice and the Agreement. The number of PSUs ultimately paid out to you will range from 0% to 100% of the Target Number of PSUs as
determined based on the terms contained on the attached <U>Exhibit A</U> and based upon the Company&#146;s achievement of the performance goal set forth on <U>Exhibit A</U> (the &#147;<U>Performance Goal</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Certification Date</I></B>&#148; means the date on which the Committee certifies whether the Performance Goals have been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Vesting Upon Termination of Service</U>: The following shall apply if your Service terminates during the Performance Period: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the termination of your Service during the Performance Period for any reason other than due to your
termination by the Company without Cause or your Qualified Retirement that satisfies the requirements of Section&nbsp;4 of the Agreement, none of the Target Number of PSUs will be eligible to vest. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the termination of your Service during the Performance Period due to your termination by the Company
without Cause, if the Performance Goal has already been achieved at the time of such termination, then the PSUs will vest in accordance with the schedule on <U>Exhibit A</U>. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the termination of your Service during the Performance Period due to your termination by the Company
without Cause, if the Performance Goal has not been achieved at the time of your termination, then none of the Target Number of PSUs will be eligible to vest and the PSUs will be forfeited in their entirety as of such termination of your Service.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon termination of your Service during the Performance Period due to a Qualified Retirement that satisfies the
requirements of Section&nbsp;4 of the Agreement, the PSUs will be subject to the terms of Section&nbsp;4 of the Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
you hereby agree that, notwithstanding the terms of any employment agreement, employment offer letter, severance agreement or other severance arrangements between you and the Company or any of its Affiliates (each, a &#147;<B><I>Severance
Arrangement</I></B>&#148;), the PSUs shall not be subject to any additional acceleration of vesting pursuant to the terms of any Severance Arrangement or any subsequent severance plan or arrangement adopted by or implemented by the Company or any of
its Affiliates or any of their successors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Vesting Upon a Change in Control</U>: Notwithstanding anything to the contrary in this Notice or the
Agreement, if you remain in continuous Service until the closing of a Change in Control, the Target Number of PSUs eligible to vest during the Performance Period before the closing of the Change in Control will be determined by the Committee in its
sole discretion in accordance with <U>Exhibit A</U>, effective as of immediately prior to the closing of the Change in Control. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lindsey Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">8/9/2024</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Axogen, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Date</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I acknowledge that I have carefully read the Agreement.&nbsp;I agree to be bound by all of the provisions set forth in the Agreement.&nbsp;I also consent to
electronic delivery of all notices or other information with respect to the PSUs or the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Dale</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">8/9/2024</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature of Grantee</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Date</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AXOGEN, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERFORMANCE-BASED RESTRICTED STOCK UNITS AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDUCEMENT AWARD </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Terminology</U>. Unless otherwise provided in this Agreement, capitalized terms used herein are defined in Glossary at the end of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Vesting</U>. All of the PSUs are nonvested and forfeitable as of the Grant Date.&nbsp;The PSUs will become
vested and nonforfeitable in accordance with the vesting terms and conditions set forth in the Notice and <U>Exhibit A</U>.&nbsp;Except for the circumstances, if any, described in the Notice, or as otherwise provided in Section&nbsp;4 below, none of
the PSUs will become vested and nonforfeitable after your Service ceases. Any PSUs that do not satisfy the Performance Goals during the Performance Period, unless forfeited earlier, will be forfeited immediately upon the Certification Date for the
full Performance Period upon which the Committee determines that such Performance Goals have not been achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Termination
of Service</U>. Except as otherwise provided in Section&nbsp;4 below, or as otherwise provided in the Notice, if your Service with the Company ceases for any reason, all PSUs that are not then vested and nonforfeitable will be forfeited to the
Company immediately and automatically upon such cessation without payment of any consideration therefor and you will have no further right, title or interest in or to such PSUs or the underlying shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Qualified Retirement</U>. If your title with the Company as of the Grant Date of the PSUs is Vice President or above, in the event
your Service with the Company ceases by reason of a Qualified Retirement during the Performance Period, and such Qualified Retirement occurs on a date that is at least twelve (12)&nbsp;months following the Grant Date, (i)&nbsp;if you have at least
ten (10)&nbsp;years of continuous Service but less than fifteen (15)&nbsp;years of continuous Service as of the date of your Qualified Retirement, then the Target Number of PSUs will continue to be eligible to become vested and nonforfeitable based
on actual performance in accordance with the vesting terms and conditions set forth in the Notice and <U>Exhibit A</U>; provided, that the Target Number of PSUs that are eligible to vest shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT>
based on the number of days of your Service in the Performance Period (and for the avoidance of doubt, any <FONT STYLE="white-space:nowrap">pro-rated</FONT> amount for a partial Calendar Year during which the Qualified Retirement occurs will be
eligible to vest based on actual performance for such Calendar Year) and (ii)&nbsp;if you have at least fifteen (15)&nbsp;years of continuous Services as of the date of your Qualified Retirement, then the full Target Number of PSUs will continue to
be eligible to become vested and nonforfeitable during the Performance Period based on actual performance in accordance with the vesting schedule set forth in the Notice. Notwithstanding the foregoing, all vesting shall cease and any remaining PSUs
that are not then vested and nonforfeitable will be forfeited to the Company immediately and automatically upon your death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Restrictions on Transfer</U>. Neither this Agreement nor any of the PSUs may be assigned, transferred, pledged, hypothecated or
disposed of in any way, whether by operation of law or otherwise, and the PSUs shall not be subject to execution, attachment or similar process.&nbsp;All rights with respect to this Agreement and the PSUs shall be exercisable during your lifetime
only by you or your guardian or legal representative.&nbsp;Notwithstanding the foregoing, the PSUs, to the extent outstanding, may be transferred upon your death by last will and testament or under the laws of descent and distribution.
Notwithstanding the foregoing, except as otherwise restricted by applicable law, the Committee may, but need not, permit the PSUs to be transferred to one of your Family Members (as defined below) as a gift or pursuant to a domestic relations order
in settlement of marital property rights. The Committee shall not permit any transfer of the PSUs for value. For purposes of this Section<U></U>&nbsp;5, &#147;<B><I>Family Member</I></B>&#148; means any child, stepchild, grandchild, parent,
stepparent, grandparent, spouse, former spouse, sibling, niece, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nephew, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including adoptive relationships, any person sharing your household (other than a tenant or employee), a trust in which these persons have more than 50%
of the beneficial interest, a foundation in which these persons (or you) control the management of assets, and any other entity in which these persons (or you) own more than 50% of the voting interests. The following transactions are not prohibited
transfers for value: (i)&nbsp;a transfer under a domestic relations order in settlement of marital property rights; and (ii)&nbsp;a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or you) in exchange
for an interest in that entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Settlement of PSUs</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Manner of Settlement</U>. You are not required to make any monetary payment (other than applicable tax withholding, if required)
as a condition to settlement of the PSUs.&nbsp;The Company will issue to you, in settlement of your PSUs and subject to the provisions of Section&nbsp;7 below, the number of whole shares of Common Stock that equals the number of whole PSUs that
become vested, and such vested PSUs will terminate and cease to be outstanding upon such issuance of the shares.&nbsp;Upon issuance of such shares, the Company will determine the form of delivery (e.g., a stock certificate or electronic entry
evidencing such shares) and may deliver such shares on your behalf electronically to the Company&#146;s designated stock plan administrator or such other broker-dealer as the Company may choose at its sole discretion, within reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Timing of Settlement</U>. Your PSUs, to the extent vested, will be settled by the Company, via the issuance of Common Stock as
described herein, within thirty (30)&nbsp;days following the Certification Date on which the Committee certifies that the Performance Goal has been met and that the PSUs have vested (the &#147;<B><I>Issuance Date</I></B>&#148;). In no event will you
be permitted, directly or indirectly, to designate the Issuance Date. However, if a scheduled Issuance Date falls on a Saturday, Sunday or federal holiday, such Issuance Date shall instead fall on the next following day that the principal executive
offices of the Company are open for business. Notwithstanding the foregoing, in the event that (i)&nbsp;you are subject to the Company&#146;s policy permitting officers and directors to sell shares only during certain &#147;window&#148; periods, in
effect from time to time or you are otherwise prohibited from selling shares of the Company&#146;s Common Stock in the public market and any shares covered by your PSUs are scheduled to be issued on a day (the &#147;<B><I>Original Distribution
Date</I></B>&#148;) that does not occur during an open &#147;window period&#148; applicable to you, as determined by the Company in accordance with such policy, or does not occur on a date when you are otherwise permitted to sell shares of the
Company&#146;s Common Stock in the open market, and (ii)&nbsp;the Company elects not to satisfy its tax withholding obligations by withholding shares from your distribution, then, solely to the extent permitted by Section&nbsp;409A (as defined
below), such shares shall not be issued and delivered on such Original Distribution Date and shall instead be issued and delivered on the first business day of the next occurring open &#147;window period&#148; applicable to you pursuant to such
policy (regardless of whether you are still providing continuous services at such time) or the next business day when you are not prohibited from selling shares of the Company&#146;s Common Stock in the open market, but in no event later than
December 31<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> of the calendar year in which the Issuance Date occurs, or if later, by the 15th day of the third calendar month of the calendar year following the Issuance Date, or if later, by the
15th day of the third calendar month of the calendar year following the Issuance Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>Tax Withholding</U>. On or before the
time you receive a distribution of the shares subject to your PSUs, or at any time thereafter as requested by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate
provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate which arise in connection with your PSUs (the &#147;<B><I>Withholding </I></B>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B><I>Taxes</I></B>&#148;).&nbsp;Additionally, the Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your PSUs by any of the
following means or by a combination of such means: (i)&nbsp;withholding from any compensation otherwise payable to you by the Company; (ii)&nbsp;causing you to tender a cash payment; (iii)&nbsp;permitting you to enter into a &#147;same day
sale&#148; commitment with a broker-dealer that is a member of the Financial Industry Regulatory Authority (a &#147;<B><I>FINRA Dealer</I></B>&#148;) whereby you irrevocably elect to sell a portion of the shares to be delivered under the Agreement
to satisfy the Withholding Taxes and whereby the FINRA Dealer irrevocably commits to forward the proceeds necessary to satisfy the Withholding Taxes directly to the Company; or (iv)&nbsp;withholding shares of Common Stock from the shares of Common
Stock issued or otherwise issuable to you in connection with the PSUs with a Fair Market Value (measured as of the date shares of Common Stock are issued to you pursuant to Section&nbsp;6 of this Agreement) equal to the amount of such Withholding
Taxes; provided, however, that the number of such shares of Common Stock so withheld shall not exceed, by more than the Fair Market Value of one share of Common Stock, the amount necessary to satisfy the Company&#146;s required tax withholding
obligations using the minimum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income.&nbsp;Unless the tax withholding obligations of the Company
and/or any Affiliate are satisfied, the Company shall have no obligation to deliver to you any Common Stock.&nbsp;In the event the Company&#146;s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined after
the delivery of Common Stock to you that the amount of the Company&#146;s withholding obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold
the proper amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Adjustments for Corporate Transactions and Other Events</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Mandatory Adjustments</U>. In the event of a merger, consolidation, stock rights offering, statutory share exchange or similar
event affecting Axogen (each, a &#147;<B><I>Corporate Event</I></B>&#148;) or a stock dividend, stock split, reverse stock split, separation, spinoff, reorganization, extraordinary dividend of cash or other property, share combination or
subdivision, or recapitalization or similar event affecting the capital structure of Axogen (each, a &#147;<B><I>Share Change</I></B>&#148;) that occurs at any time after the Grant Date, the Committee shall make equitable and appropriate
substitutions or proportionate adjustments to (i)&nbsp;the aggregate number and kind of shares of Common Stock or other securities on which the Award is granted, (ii)&nbsp;the number of shares of Common Stock or other securities covered by the Award
and other relevant terms of the Award, and (iii)&nbsp;all other numerical limitations relating to the Awards; <I>provided</I>, <I>however</I>, that any fractional shares resulting from any such adjustment shall be eliminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Discretionary Adjustments</U>. In the case of Corporate Events, the Committee may make such other adjustments to the Award as it
determines to be appropriate and desirable, which adjustments may include, without limitation, (i)&nbsp;the cancellation of the Award in exchange for payments of cash, securities or other property or a combination thereof having an aggregate value
equal to the value of the Award, as determined by the Committee in its sole discretion, (ii)&nbsp;the substitution of securities or other property (including, without limitation, cash or other securities of Axogen and securities of entities other
than Axogen) for the shares of Common Stock subject to the Award, and (iii)&nbsp;the substitution of equivalent awards, as determined in the sole discretion of the Committee, of the surviving or successor entity or a parent thereof
(&#147;<B><I>Substitute Awards</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Adjustments to Performance Goals</U>. The Committee may, in its discretion,
adjust the Performance Goal applicable to the Award to reflect any unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> events and other extraordinary items, impact of charges for restructurings, discontinued operations and the
cumulative effects of accounting or tax changes, each as defined by generally accepted accounting principles or as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identified in Axogen&#146;s consolidated financial statements, notes to the consolidated financial statements, management&#146;s discussion and analysis or other Axogen filings with the
Securities and Exchange Commission. If the Committee determines that a change in the business, operations, corporate structure or capital structure of Axogen or the applicable subsidiary, business segment or other operational unit of Axogen or any
such entity or segment, or the manner in which any of the foregoing conducts its business, or other events or circumstances, render the Performance Goals to be unsuitable, the Committee may modify such Performance Goals or the related minimum
acceptable level of achievement, in whole or in part, as the Committee deems appropriate and equitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<U>Statutory
Requirements Affecting Adjustments</U>. Notwithstanding the foregoing: (i)&nbsp;any adjustments made pursuant to this Section&nbsp;8 to the Award that are considered &#147;deferred compensation&#148; within the meaning of Section&nbsp;409A of the
Code shall be made in compliance with the requirements of Section&nbsp;409A of the Code; (ii)&nbsp;any adjustments made pursuant to this Section&nbsp;8 that are not considered &#147;deferred compensation&#148; subject to Section&nbsp;409A of the
Code shall be made in such a manner as to ensure that after such adjustment, the Award either (A)&nbsp;continues not to be subject to Section&nbsp;409A of the Code or (B)&nbsp;complies with the requirements of Section&nbsp;409A of the Code; and
(iii)&nbsp;in any event, the Committee shall not have the authority to make any adjustments pursuant to this Section&nbsp;8 to the extent the existence of such authority would cause the Award that is not intended to be subject to Section&nbsp;409A
of the Code at the date of grant to be subject thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<U>Dissolution or Liquidation</U><I>.</I> Unless the Committee
determines otherwise, the Award shall terminate upon the dissolution or liquidation of Axogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<U>Non</U><U><FONT
STYLE="white-space:nowrap">-Guarantee</FONT> of Employment or Service Relationship</U>. Nothing in this Agreement shall alter your <FONT STYLE="white-space:nowrap">at-will</FONT> or other employment status or other service relationship with the
Company, nor be construed as a contract of employment or service relationship between the Company and you, or as a contractual right of you to continue in the employ of, or in a service relationship with, the Company for any period of time, or as a
limitation of the right of the Company to discharge you at any time with or without cause or notice and whether or not such discharge results in the forfeiture of any nonvested and forfeitable PSUs or any other adverse effect on your interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Rights as Stockholder</U>. You shall not have any of the rights of a stockholder with respect to any shares of Common Stock that
may be issued in settlement of the PSUs until such shares of Common Stock have been issued to you.&nbsp;No adjustment shall be made for dividends, distributions, or other rights for which the record date is prior to the date such shares are issued,
except as provided in Section&nbsp;8 of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>The Company&#146;s Rights</U>. The existence of the PSUs shall not
affect in any way the right or power of the Company or its stockholders to make or authorize any or all adjustments, recapitalizations, reorganizations, or other changes in the Company&#146;s capital structure or its business, or any merger or
consolidation of the Company, or any issue of bonds, debentures, preferred or other stocks with preference ahead of or convertible into, or otherwise affecting the Common Stock or the rights thereof, or the dissolution or liquidation of the Company,
or any sale or transfer of all or any part of the Company&#146;s assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Restrictions on Issuance of Shares</U>. The issuance of shares of Common Stock upon settlement of the PSUs shall be subject to
and in compliance with all applicable requirements of federal, state, or foreign law with respect to such securities.&nbsp;No shares of Common Stock may be issued </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hereunder if the issuance of such shares would constitute a violation of any applicable federal, state, or foreign securities laws or other law or regulations or the requirements of any stock
exchange or market system upon which the Common Stock may then be listed.&nbsp;The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company&#146;s legal counsel to be necessary to
the lawful issuance of any shares subject to the PSUs shall relieve the Company of any liability in respect of the failure to issue such shares as to which such requisite authority shall not have been obtained.&nbsp;As a condition to the settlement
of the PSUs, the Company may require you to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation, and to make any representation or warranty with respect thereto as may be
requested by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Restrictive Covenants</U>. You hereby agree to the following restrictive covenants as
consideration of the grant of the PSUs: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;You hereby agree and acknowledge that the grant of the PSUs is conditioned upon your
continued compliance with any and all confidentiality, <FONT STYLE="white-space:nowrap">non-compete</FONT> and/or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> covenants and restrictions contained in any separate agreement between you and
the Company, and if you breach any of such covenants or restrictions, upon written notice delivered to you: (i)&nbsp;the entirety of the Company&#146;s obligations under this Agreement shall terminate in their entirety, (ii)&nbsp;all PSUs that are
not then vested and nonforfeitable will be forfeited to the Company immediately and automatically, and (iii)&nbsp;you shall have no further rights or privileges under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<U>Notices</U>. All notices and other communications made or given pursuant to this Agreement shall be given in writing and shall be
deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5)&nbsp;days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company, or in
the case of notices delivered to the Company by you, addressed to the Committee, care of the Company for the attention of its Secretary at its principal executive office or, in either case, if the receiving party consents in advance, transmitted and
received via telecopy or via such other electronic transmission mechanism as may be available to the parties.&nbsp;Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to this award of PSUs
by electronic means or to request your consent to accept this award of PSUs by electronic means.&nbsp;You hereby consent to receive such documents by electronic delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<U>Entire Agreement</U>. This Agreement, together with the relevant Notice, contain the entire agreement between the parties with
respect to the PSUs granted hereunder.&nbsp;Any oral or written agreements, representations, warranties, written inducements, or other communications made prior to the execution of this Agreement with respect to the PSUs granted hereunder shall be
void and ineffective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&#8195;<U>Amendment</U>. This Agreement may be amended from time to time by the Committee in
its discretion; <U>provided</U>, <U>however</U>, that this Agreement may not be modified in a manner that would have a materially adverse effect on the PSUs as determined in the discretion of the Committee, except as provided in a written document
signed by each of the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&#8195;<U>Change in Control Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>Termination of Award</U>. Notwithstanding the provisions of Section<U></U>&nbsp;17(b), in the event that any transaction
resulting in a Change in Control occurs, the Award, if outstanding at such time, will terminate upon the effective time of such Change in Control unless provision is made in connection with the transaction for the continuation or assumption of the
Award by, or for the issuance therefor of a Substitute Award of, the surviving or successor entity or a parent thereof. Solely with respect to if the Award will terminate as a result of the immediately preceding sentence, the vesting and earnings of
the Award shall be as provided for in <U>Exhibit A</U> on the occurrence of a Change in Control during the Performance Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Continuation, Assumption or Substitution of Awards</U>. The Committee may specify, on or after the Grant Date, the consequences
of your termination of Service that occurs coincident with or following the occurrence of a Change in Control, if a Change in Control occurs under which provision is made in connection with the transaction for the continuation or assumption of
outstanding Awards by, or for the issuance therefor of Substitute Awards of, the surviving or successor entity or a parent thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Other Permitted Actions</U>. In the event that any transaction resulting in a Change in Control occurs, the Committee may take
any of the actions set forth in Section<U></U> 8 with respect to the Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&#8195;<U>409A Savings Clause</U>. This Agreement and the
PSUs granted hereunder are intended to be exempt from or comply with the requirements of Section&nbsp;409A of the Code and the regulations and IRS guidance promulgated thereunder
(&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;).&nbsp;In administering this Agreement, the Company shall interpret this Agreement in a manner consistent with Section&nbsp;409A. To the extent necessary to comply with
Section&nbsp;409A, if you are a &#147;Specified Employee&#148; (within the meaning set forth Section&nbsp;409A(a)(2)(B)(i) of the Code) as of the date of your separation from service (within the meaning of Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)),</FONT> then the issuance of any shares that would otherwise be made upon the date of the separation from service or within the first six (6)&nbsp;months thereafter will not be made on the
originally scheduled date(s) and will instead be issued in a lump sum on the date that is six (6)&nbsp;months and one day after the date of the separation from service, but if and only if such delay in the issuance of the shares is necessary to
avoid the imposition of additional taxation on you in respect of the shares under Section&nbsp;409A.&nbsp;Each installment of shares that vests is intended to constitute a &#147;separate payment&#148; for purposes of Section&nbsp;409A and Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2).&nbsp;For</FONT> purposes of Section&nbsp;409A, the payment of dividend equivalents under this Agreement, if any, shall be construed as earnings and the time and form of payment
of such dividend equivalents shall be treated separately from the time and form of payment of the underlying PSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&#8195;<U>No
Obligation to Minimize Taxes</U>.&nbsp;The Company has no duty or obligation to minimize the tax consequences to you of this award of PSUs and shall not be liable to you for any adverse tax consequences to you arising in connection with this
award.&nbsp;You are hereby advised to consult with your own personal tax, financial and/or legal advisors regarding the tax consequences of this award and by signing the Notice, you have agreed that you have done so or knowingly and voluntarily
declined to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&#8195;<U>No Funding</U>.&nbsp;This Agreement constitutes an unfunded and unsecured promise by the Company to issue
shares of Common Stock in the future in accordance with its terms.&nbsp;You have the status of a general unsecured creditor of the Company as a result of receiving the grant of PSUs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&#8195;<U>Effect on Other Employee Benefit Plans</U>.&nbsp;The value of the PSUs subject
to this Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise
expressly provides.&nbsp;The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#146;s or any Affiliate&#146;s employee benefit plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&#8195;<U>Governing Law</U>.&nbsp;The validity, construction and effect of this Agreement, and of any determinations or decisions made by
the Committee relating to this Agreement, and the rights of any and all persons having or claiming to have any interest under this Agreement, shall be determined exclusively in accordance with the laws of the State of Minnesota, without regard to
its provisions concerning the applicability of laws of other jurisdictions.&nbsp;As a condition of this Agreement, you agree that you will not bring any action arising under, as a result of, pursuant to or relating to, this Agreement in any court
other than a federal or state court in the districts which include New Jersey, and you hereby agree and submit to the personal jurisdiction of any federal court located in the district which includes New Jersey or any state court in the district
which includes New Jersey.&nbsp;You further agree that you will not deny or attempt to defeat such personal jurisdiction or object to venue by motion or other request for leave from any such court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23.&#8195;<U>Resolution of Disputes</U>.&nbsp;Any dispute or disagreement which shall arise under, or as a result of, or pursuant to or
relating to, this Agreement shall be determined by the Committee in good faith in its absolute and uncontrolled discretion, and any such determination or any other determination by the Committee under or pursuant to this Agreement and any
interpretation by the Committee of the terms of this Agreement, will be final, binding and conclusive on all persons affected thereby.&nbsp;You agree that before you may bring any legal action arising under, as a result of, pursuant to or relating
to, this Agreement you will first exhaust your administrative remedies before the Committee.&nbsp;You further agree that in the event that the Committee does not resolve any dispute or disagreement arising under, as a result of, pursuant to or
relating to, this Agreement to your satisfaction, no legal action may be commenced or maintained relating to this Agreement more than twenty-four (24)&nbsp;months after the Committee&#146;s decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24.&#8195;<U>Headings</U>.&nbsp;The headings in this Agreement are for reference purposes only and shall not affect the meaning or
interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25.&#8195;<U>Electronic Delivery of Documents</U>.&nbsp;By your signing the Notice, you
(i)&nbsp;consent to the electronic delivery of this Agreement, all information with respect to the PSUs, and any reports of the Company provided generally to the Company&#146;s stockholders; (ii)&nbsp;acknowledge that you may receive from the
Company a paper copy of any documents delivered electronically at no cost to you by contacting the Company by telephone or in writing; (iii)&nbsp;further acknowledge that you may revoke your consent to the electronic delivery of documents at any
time by notifying the Company of such revoked consent by telephone, postal service or electronic mail; and (iv)&nbsp;further acknowledge that you understand that you are not required to consent to electronic delivery of documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26.&#8195;<U>No Future Entitlement</U>.&nbsp;By your signing the Notice, you acknowledge and agree that:&nbsp;(i)&nbsp;the grant of a
restricted stock unit award is a <FONT STYLE="white-space:nowrap">one-time</FONT> benefit which does not create any contractual or other right to receive future grants of restricted stock units, or compensation in lieu of restricted stock units,
even if restricted stock units have been granted repeatedly in the past; (ii)&nbsp;all determinations with respect to any such future grants and the terms thereof will be at the sole discretion of the Committee; (iii)&nbsp;the value of the
restricted stock units is an extraordinary item of compensation which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is outside the scope of your employment contract, if any; (iv)&nbsp;the value of the restricted stock units is not part of normal or expected compensation or salary for any purpose, including,
but not limited to, calculating any termination, severance, resignation, redundancy, end of service payments or similar payments, or bonuses, long-service awards, pension or retirement benefits; (v)&nbsp;the vesting of the restricted stock units
ceases upon termination of Service with the Company or transfer of employment from the Company, or other cessation of eligibility for any reason, except as may otherwise be explicitly provided in this Agreement; (vi)&nbsp;the Company does not
guarantee any future value of the restricted stock units; and (vii)&nbsp;no claim or entitlement to compensation or damages arises if the restricted stock units decrease or do not increase in value and you irrevocably release the Company from any
such claim that does arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27.&#8195;<U>Personal Data</U>.&nbsp;For purposes of the implementation, administration and management of the
restricted stock units or the effectuation of any acquisition, equity or debt financing, joint venture, merger, reorganization, consolidation, recapitalization, business combination, liquidation, dissolution, share exchange, sale of stock, sale of
material assets or other similar corporate transaction involving the Company (a &#147;<B><I>Corporate Transaction</I></B>&#148;), you consent, by execution of the Notice, to the collection, receipt, use, retention and transfer, in electronic or
other form, of your personal data by and among the Company and its third party vendors or any potential party to a potential Corporate Transaction.&nbsp;You understand that personal data (including but not limited to, name, home address, telephone
number, employee number, employment status, social security number, tax identification number, date of birth, nationality, job and payroll location, data for tax withholding purposes and shares awarded, cancelled, vested and unvested) may be
transferred to third parties assisting in the implementation, administration and management of the restricted stock units or the effectuation of a Corporate Transaction and you expressly authorize such transfer as well as the retention, use, and the
subsequent transfer of the data by the recipient(s).&nbsp;You understand that these recipients may be located in your country or elsewhere, and that the recipient&#146;s country may have different data privacy laws and protections than your
country.&nbsp;You understand that data will be held only as long as is necessary to implement, administer and manage the restricted stock units or effect a Corporate Transaction.&nbsp;You understand that you may, at any time, request a list with the
names and addresses of any potential recipients of the personal data, view data, request additional information about the storage and processing of data, require any necessary amendments to data or refuse or withdraw the consents herein, in any case
without cost, by contacting in writing the Company&#146;s Secretary.&nbsp;You understand, however, that refusing or withdrawing your consent may affect your ability to accept a restricted stock unit award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">{<I>Glossary begins on next page</I>} </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GLOSSARY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;&#147;<B><I>Affiliate</I></B><I>&#148;</I> means any entity, whether now or hereafter existing, which controls, is controlled by, or
is under common control with, Axogen or any successor to Axogen. For this purpose, &#147;control&#148; (including the correlative meanings of the terms &#147;controlled by&#148; and &#147;under common control with&#148;) shall mean ownership,
directly or indirectly, of 50% or more of the total combined voting power of all classes of voting securities issued by such entity, or the possession, directly or indirectly, of the power to direct the management and policies of such entity, by
contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;&#147;<B><I>Agreement</I></B>&#148; means this document, as amended from time to time, together with the
Notice which is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;&#147;<B><I>Board</I></B>&#148; means the Board of Directors of Axogen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;&#147;<B><I>Cause</I></B>&#148; means as such term is defined in the Executive Employment Agreement between the Company and you
dated effective as of August&nbsp;9, 2024 as may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;&#147;<B><I>Change in Control</I></B>&#148;
means the first of the following to occur: (i)&nbsp;a Change in Ownership of Axogen, (ii)&nbsp;a Change in Effective Control of Axogen, or (iii)&nbsp;a Change in the Ownership of Assets of Axogen, as described herein and construed in accordance with
Code section 409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">a.&#8195;A &#147;Change in Ownership of Axogen&#148; shall occur on the date that any one Person acquires, or Persons
Acting as a Group acquire, ownership of the capital stock of Axogen that, together with the stock held by such Person or Group, constitutes more than 50% of the total fair market value or total voting power of the capital stock of Axogen. However,
if any one Person is, or Persons Acting as a Group are, considered to own more than 50%, on a fully diluted basis, of the total fair market value or total voting power of the capital stock of Axogen, the acquisition of additional stock by the same
Person or Persons Acting as a Group is not considered to cause a Change in Ownership of Axogen or to cause a Change in Effective Control of Axogen (as described below). An increase in the percentage of capital stock owned by any one Person, or
Persons Acting as a Group, as a result of a transaction in which Axogen acquires its stock in exchange for property will be treated as an acquisition of stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">b.&#8195;A &#147;Change in Effective Control of Axogen&#148; shall occur on the date either (A)&nbsp;a majority of members of Axogen&#146;s
Board is replaced during any <FONT STYLE="white-space:nowrap">12-month</FONT> period by Directors whose appointment or election is not endorsed by a majority of the members of Axogen&#146;s Board before the date of the appointment or election, or
(B)&nbsp;any one Person, or Persons Acting as a Group, acquires (or has acquired during the <FONT STYLE="white-space:nowrap">12-month</FONT> period ending on the date of the most recent acquisition by such Person or Persons) ownership of stock of
Axogen possessing 50% or more of the total voting power of the stock of Axogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">c.&#8195;A &#147;Change in the Ownership of Assets of
Axogen&#148; shall occur on the date that any one Person acquires, or Persons Acting as a Group acquire (or has or have acquired during the <FONT STYLE="white-space:nowrap">12-month</FONT> period ending on the date of the most recent acquisition by
such Person or Persons), assets from Axogen that have a total gross fair market value equal to or more than 51% of the total gross fair market value of all of the assets of Axogen immediately before such acquisition or acquisitions. For this
purpose, gross fair market value means the value of the assets of Axogen, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following rules of construction apply in interpreting the definition of Change in
Control: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A)&#8195;A &#147;<B><I>Person</I></B>&#148; means any individual, entity or group within the meaning of Section&nbsp;13(d)(3)
or 14(d)(2) of the Securities Exchange Act of 1934, as amended, other than employee benefit plans sponsored or maintained by Axogen and by entities controlled by Axogen or an underwriter, initial purchaser or placement agent temporarily holding the
capital stock of Axogen pursuant to a registered public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B)&#8195;Persons will be considered to be Persons Acting as a Group
(or Group) if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the corporation. If a Person owns stock in both corporations that enter into a merger,
consolidation, purchase or acquisition of stock, or similar transaction, such shareholder is considered to be acting as a Group with other shareholders only with respect to the ownership in that corporation before the transaction giving rise to the
change and not with respect to the ownership interest in the other corporation. Persons will not be considered to be acting as a Group solely because they purchase assets of the same corporation at the same time or purchase or own stock of the same
corporation at the same time, or as a result of the same public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(C)&#8195;A Change in Control shall not include a transfer to
a related person as described in Code section 409A or a public offering of capital stock of Axogen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(D)&#8195;For purposes of the
definition of Change in Control, Section&nbsp;318(a) of the Code applies to determine stock ownership. Stock underlying a vested option is considered owned by the individual who holds the vested option (and the stock underlying an unvested option is
not considered owned by the individual who holds the unvested option). For purposes of the preceding sentence, however, if a vested option is exercisable for stock that is not substantially vested (as defined by Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.83-3(b)</FONT> and (j)), the stock underlying the option is not treated as owned by the individual who holds the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<I>&#147;</I><B><I>Code</I></B><I>&#148; </I>means the Internal Revenue Code of 1986, as amended from time to time, and any
successor thereto, the Treasury Regulations thereunder and other relevant interpretive guidance issued by the Internal Revenue Service or the Treasury Department. Reference to any specific section of the Code shall be deemed to include such
regulations and guidance, as well as any successor section, regulations and guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<I>&#147;</I><B><I>Committee</I></B><I>&#148;</I> means the Compensation Committee of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&#8195;<I>&#147;</I><B><I>Common Stock</I></B><I>&#148; </I>means shares of common stock of Axogen, par value $0.01 per share, and any
capital securities into which they are converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<I>&#147;</I><B><I>Director</I></B>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&#8195;<I>&#147;</I><B><I>Fair Market Value</I></B>&#148; means, on a per share basis as of any date, unless otherwise determined by the
Committee: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">a.&#8195;if the principal market for the Common Stock (as determined by the Committee if the Common Stock is listed or
admitted to trading on more than one exchange or market) is a national securities exchange or an established securities market, the official closing price per share of Common Stock for the regular market session on that date on the principal
exchange or market on which the Common Stock is then listed or admitted to trading or, if no sale is reported for that date, on the last preceding day on which a sale was reported, all as reported by such source as the Committee may select; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">b.&#8195;if the principal market for the Common Stock is not a national securities exchange
or an established securities market, but the Common Stock is quoted by a national quotation system, the average of the highest bid and lowest asked prices for the Common Stock on that date as reported on a national quotation system or, if no prices
are reported for that date, on the last preceding day on which prices were reported, all as reported by such source as the Committee may select; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">c.&#8195;if the Common Stock is neither listed or admitted to trading on a national securities exchange or an established securities market,
nor quoted by a national quotation system, the value determined by the Committee in good faith by the reasonable application of a reasonable valuation method, which method may, but need not, include taking into account an appraisal of the fair
market value of the Common Stock conducted by a nationally recognized appraisal firm selected by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
preceding, for foreign, federal, state and local income tax reporting purposes and for such other purposes as the Committee deems appropriate, the Fair Market Value shall be determined by the Committee in accordance with uniform and
nondiscriminatory standards adopted by it from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&#8195;&#147;<B><I>Grant Date</I></B>&#148; means the effective date of a
grant of PSUs made to you as set forth in the relevant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&#8195;&#147;<B><I>Notice</I></B>&#148; means the statement, letter or
other written notification provided to you by the Company setting forth the terms of a grant of PSUs made to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&#8195;&#147;<B><I>PSU</I></B>&#148;&nbsp;means the Company&#146;s commitment to issue one share of Common Stock at a future date, subject
to the terms of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&#8195;&#147;<B><I>Qualified Retirement</I></B>&#148; means the termination of your Service after
attainment of age sixty (60)&nbsp;with at least ten (10)&nbsp;years of continuous service, provided that: (i)&nbsp;as a Vice-President or above, if you elect to terminate your Service voluntarily, you have provided the Company with at least twelve
(12)&nbsp;months&#146; advance notice of your retirement date or such other term of advance notice as is determined by the Chief Human Resources Officer of the Company; (ii)&nbsp;as a Vice-President or above, if the Company elected to terminate your
Service, such termination is without Cause and (iii)&nbsp;during the three (3)&nbsp;years prior to the year in which such termination of Service occurs, you have maintained consistent historical performance reviews. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&#8195;&#147;<B>Service</B>&#148; means your employment, service as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director, or
other service relationship with the Company and its Affiliates.&nbsp;Your Service will be considered to have ceased with the Company and its Affiliates if, immediately after a sale, merger, or other corporate transaction, the trade, business, or
entity with which you are employed or otherwise have a service relationship is not Axogen, Inc., or its successor or an Affiliate of Axogen, Inc. or its successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&#8195;&#147;<B><I>You</I></B>&#148; or &#147;<B><I>Your</I></B>&#148; means the recipient of the PSUs as reflected on the applicable
Notice.&nbsp;Whenever the word &#147;you&#148; or &#147;your&#148; is used in any provision of this Agreement under circumstances where the provision should logically be construed, as determined by the Committee, to apply to the estate, personal
representative, or beneficiary to whom the PSUs may be transferred by will or by the laws of descent and distribution, the words &#147;you&#148; and &#147;your&#148; shall be deemed to include such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">{<I>End of Agreement}</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Terms of Performance Restricted Stock Units </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Performance Vesting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Performance
Period and Allocation of Target Number of PSUs </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Performance Period is the period beginning January 1, 2024 and ending December 31, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Target Number of PSUs will fully vest upon FDA&#146;s approval of the Company&#146;s biologics license application for Avance Nerve Graft (the
&#147;<B><I>Performance Goal</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, the Performance Goal is deemed achieved on the Certification Date on which
the Committee certifies that the Performance Goal has been achieved by the Company. Notwithstanding the foregoing and anything to the contrary in this Agreement, none of the PSUs shall vest prior to the
<FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the Grant Date, regardless of whether the Performance Goal is achieved prior to such <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you remain in continuous Service through the achievement of the Performance Goal and through the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of the Grant Date, 100% of the Target Number of PSUs will vest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Service During Performance Period </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your Service terminates during the Performance Period for any reason other than due to a Qualified Retirement, the PSUs will be forfeited in their entirety
if the Performance Goal has not been achieved and certificated while you remained in Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your Service terminates during the Performance Period
due to your termination by the Company without Cause and the Performance Goal has already been achieved at the time of such termination, then the PSUs will vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the Grant Date,
if not previously vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, if your Service terminates prior to the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of the Grant Date for any reason other than due to a Qualified Retirement or a termination by the Company without Cause, none of your PSUs shall vest and you shall forfeit your PSUs in their entirety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your Service terminates during the Performance Period due to a Qualified Retirement, the PSUs will remain eligible to vest as set forth in Section&nbsp;4
of the Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Occurrence of a Change in Control During Performance Period </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the closing of a Change in Control occurs during the Performance Period, subject to the terms of the Notice, the Committee will determine, in its sole
discretion, to what extent any of the PSU will vest prior to the date of the closing of the Change in Control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d831362dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g831362g0808225256062.jpg" ALT="LOGO" STYLE="width:2.88611in;height:0.890278in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Axogen, Inc. Announces New Leadership Appointments </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>The Board of Directors appoints Michael Dale as new CEO and Director, effective August</I><I></I><I>&nbsp;9,
2024</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dale replaces Karen Zaderej, who will remain in an advisory role for nine months</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Current Member of the Board, Paul Thomas, will be the new Chairman of the Board, effective
August</I><I></I><I>&nbsp;9, 2024</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ALACHUA, FL. and TAMPA, FL., August&nbsp;8, 2024 (GLOBAL NEWSWIRE)&#150; Axogen, Inc. (NASDAQ:
AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective
August&nbsp;9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for nine months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The move aligns the executive team with the
Company&#146;s needs going forward as Axogen focuses on commercial expansion, broad-based revenue growth, and driving toward sustainable positive cash flow and profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;On behalf of the Board of Directors, I offer my deep gratitude to Karen for her contributions over the past 18 years. Karen was integral to
Axogen&#146;s accomplishments and the development of the peripheral nerve repair market,&#148; commented Amy Wendell, Axogen&#146;s Lead Director. &#147;The Board appreciates her countless contributions and wishes her well in her future
endeavors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are thrilled to welcome Michael Dale as our new CEO and a director on our board. His strong track record as a global medical
technology company executive makes him the right leader to advance Axogen&#146;s mission to revolutionize the science of nerve repair. He brings a wealth of experience in strategic leadership, innovation, and operational excellence,&#148; Wendell
added. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An accomplished medical device executive, Mr.&nbsp;Dale has over 30 years of experience leading transformative, high-technology medical device
companies in the cardiovascular, neuromodulation, diabetes, and electrophysiology markets. His past executive leadership roles span both public and private medical device companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;It is with pride and excitement that I embark today on a new mission as leader of Axogen,&#148; commented Michael Dale. &#147;I have been fortunate to
be a part of many great healthcare businesses throughout my career. Each has been dedicated to fulfilling a credible business purpose based on unique advantages, hallmarks of a successful business. Axogen&#146;s technologies and dedication to
restoring peripheral nerve health and improving quality of life for patients who have lost sensory and or motor control function through trauma or disease embodies a unique combination of credible purpose and technological advantage. This is why I
am excited to join Axogen.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dale continued, &#147;To our shareholders and every stakeholder, my commitment on behalf of Axogen is to
build upon our strong foundation by establishing the necessary objectives, strategies, and processes to attain profitably, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> status and ensure the
fulfillment of our mission.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Axogen has also named Paul Thomas as Chairman of the Board of Directors, effective August&nbsp;9, 2024. Paul has served
as a member of the Board since 2020 and has over 30 years of leadership experience in the healthcare industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Paul has been an important
contributor to the Board and has provided invaluable guidance to the Axogen leadership team,&#148; said Wendell. &#147;The Board is pleased with his appointment to Chairman, and we look forward to our continued collaboration. Together, we will
support Micheal in executing on Axogen&#146;s strategic priorities, mission, and vision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;My conviction in Axogen continues to strengthen and I am
honored to serve as Chairman of the Board at this critical juncture,&#148; remarked Paul Thomas. &#147;I am encouraged by the strong foundation we built within the Company and look forward to working closely with Michael, the Board, and the
leadership team as the Company narrows its focus on commercial expansion, broad-based revenue growth, and driving toward sustainable positive cash flow and profitability.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with commencement of Mr.&nbsp;Dale&#146;s employment on August&nbsp;9, 2024, and as a material inducement of employment under NASDAQ Listing
Rule 5635(c)(4), Mr.&nbsp;Dale was granted 600,000 performance stock units (&#147;PSUs&#148;). Shares representing 450,000 PSUs will vest according to performance metrics tied to the achievement of Company stock price goals between February&nbsp;22,
2024 and ending February&nbsp;22, 2027 (&#147;TSR PSUs&#148;). Mr.&nbsp;Dale will earn from 0% to 200% of the TSR PSUs upon achievement of specific Company stock price goals. Shares representing 150,000 PSUs will fully vest upon approval of the
Company&#146;s biologics license application for Avance Nerve Graft<SUP STYLE="font-size:75%; vertical-align:top"> </SUP><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> during the performance period beginning from January&nbsp;1, 2024 and
ending December&nbsp;31, 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Axogen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Axogen
(AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function
and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the
pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability
to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Axogen&#146;s platform for peripheral nerve repair features a comprehensive portfolio of products used across various applications and surgical specialties,
including traumatic injuries, oral and maxillofacial surgery, breast reconstruction, and the surgical treatment of pain. These applications </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
encompass both scheduled and emergent procedures. Specifically, scheduled procedures are often pursued by patients seeking relief from conditions caused by a nerve defect or previous surgical
interventions. Such procedures include providing sensation for women undergoing breast reconstruction following a mastectomy, nerve reconstruction after the surgical removal of painful neuromas, and oral and maxillofacial procedures, as well as
nerve decompression. Conversely, emergent procedures typically arise from injuries that initially present in an emergency room, with specialists intervening either immediately or within a few days following the initial injury. This broad range of
applications underscores Axogen&#146;s vital role in addressing diverse patient needs in peripheral nerve repair. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Axogen&#146;s platform for peripheral
nerve repair features a comprehensive portfolio of products, including Avance<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Nerve Graft, a biologically active
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve
Connector<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection
for peripheral nerve injuries; Avive+ Soft Tissue Matrix <SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue
repair; and Axoguard Nerve Cap<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of
symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit www.axogeninc.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact:
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Axogen, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harold D. Tamayo, Vice President of
Finance and Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">htamayo@axogeninc.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>axgn-20240808.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 8/9/2024 5:41:10 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:axgn="http://www.axogeninc.com/20240808"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.axogeninc.com/20240808"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axgn-20240808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axgn-20240808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>axgn-20240808_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 8/9/2024 5:41:10 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>axgn-20240808_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 8/9/2024 5:41:10 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="axgn-20240808.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g831362g0808225256062.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g831362g0808225256062.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 1$# 2(  A$! Q$!_\0
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MJT7A<:J=QO,^8]ICYA'ZY_O=R/ZUUGP[\;?VC$FC:E+_ *8@Q!*W_+91V/\
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M<\;E(P?U-=;/X*NQJ+26\EN1OS!<2.=T"Y8XV8P_WVP<CMZ5QGPN_P"1V/\
MU[R_S%>VUGFM25/%-QZI%Y?3C4PZ4NC9Q/\ PJ[P]Z7'_?RBNVHKS?K5;^9G
M=]6H_P IX)\0-<?6/%-P@<_9K,F"(9XR/O'\3_(5W/P[\&065C#K-_$'O9UW
MPJXXA0]#C^\>N>U>2+_I%^#,?];,/,)]VY_G7TU&JHBHHPJ@  >E>YFLWAL/
M3P]/1/<\K+XJO6G6F.I:**^</<"BBFLP52S$  9)/:@#R'XNW(?6]/MAC,5N
MSG_@3?\ V-5?A3=>1XLD@)XN+9@/JI!_EFL'Q1JC>(?%=W=0!I%DD\J!0,DJ
MO Q]>OXU%X7U :7XHTZ[8X1)@K_[K?*?YU]C'#-9=[%[\O\ P3YAUT\9[1;7
M_P" ?1M%(*6OCCZ<**** "BBB@#"UGPAHFO2>;?V2M.!CSHV*.1[D=?QJ/3/
M!.@:2)?LUB"\J&-I)'+-M(P0">GX5T-%:JO54>3F=NUS+V-/FYN57,?2/#&C
MZ#)*^F68MVE4*Y#L<@=.IJM;^"?#UKJ"WT>G*;I7\P2/([G=Z\GDUT-%'MJM
MV^9Z[ZC]C3LERK03%<[)X&\.27K7ATU5N#)YF^.1TPV<Y&#QSZ5T=%3"I.'P
MNPY0C/XE<@N;2WO+9[:ZA2:%QADD&X'\ZY67X8^&))C(+6:,$YV).P6NQHJJ
M=>K2^"37H*=&G4^.*9GZ7HVG:+;^1IUI';QDY;:.6^IZFLWQ3XGMO#<$+7EA
M<7%O<90M&%*@_P!ULGO715!>6=MJ%K):W<*302##HXR#1":]IS5=5U[A*#Y.
M6GH>964/PWUS-RZ#3Y<Y>WDF,0_(''Y5A>.=6T2>*QTCP]%']DM69V:)2%9S
M@8'=C[UVEU\)M!FE+PSWENI/W%<,!],@G]:TM%^'NA:)<K=)%)<W"'*27#;M
MI]0!@9KUXXS#4Y*HI2E;9/9'F2PN(G'D<8J^[1H^%+&;3O"NFVEPNV:. ;U]
M"><?K1K/A71M?(?4+)'E P)5)5P/J/ZUM45X_M9\[J)V;['I^RCR*#5TCD;3
MX;>&;282_8GG(.0L\I9?RZ'\:ZM$6-%1%554855& !3Z**E:I5=YR;]0A2A3
M^!6,*Q\(:%INI#4;2Q$=T"Q$GF,?O=>"<=ZVV 92IZ$8-.HJ9SE-WD[E1A&*
MM%6,/2_"6AZ->_;-/L1#<;2N_P QCP>O4^U;E%%$YRF[R=V$81@K15@HHHJ2
MCYS\5:8^D>)]0M&!5?-,D9]48Y!_7]*]K\'>(8?$.@P3AQ]IB41W"9Y5P.OT
M/451\=>#E\2V2SVNU-1MP?+)X$B_W3_0UXW;7>J^&=59H7FLKV([71AC/L0>
M"*^E489GAHQ3M./]?B>%>6 KMM7A(^DZ*\CL?B]>QQA;_3(9V'\<,A3/X$&K
MDOQABV_N=%D+8_CG 'Z"O+>4XQ.W)^*.]9CAFK\QZ?FO-?B)XVBBMI=$TR8/
M/(-MS*AXC7NH/J>_I7):U\1=>UB-H5E2RMVX*6^0Q'NQY_+%0^%/!=_XEN%D
M*O!IP/[RX8?>]D]3[]!7?ALLCAOW^+:273^OR..OCY5_W6'6_4VOA=X=:]U4
MZQ.G^C6A*Q9'#R8_H/U-<WXOT9M#\37EIM(A9O-A/JC<C\N1^%>_:?86VF6,
M-E9Q"*WA7:BC_/6N=\<^$AXFTQ6M]JZA;Y,+'@..Z$^_\ZBAFM\8ZD](O3T7
M0NKEUL,H1^):C_ OB./7] B#R#[;;*(YUSR<=&^A'ZYKJ:^:K6[U/P[JQD@:
M6SO8#M96&#[A@>HKO+'XOW*1JM_I22N.KP2;<_@0?YTL9E%7G<\/K%CPV90Y
M>6MHT>LT5Y=/\85VG[/HK;L<&2<8_05F:?X_UW7/%.EV\DL=M:R72!H8%QN&
M>A)Y-<JRG%<KE*-DNYT/,:%THN[9[)1117FG<%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5EZOX?TK78Q'J-G'-@?*Y&&7
MZ,.11150E*,DXNS)G%2BTT>6^+/!.F:+N>TENL;2P5W4C^6:Y32=-BO[T0RO
M(JXSE",_J***^SPM2<L.Y-ZGRU>,56LD>N:'\.O#UK''<R6\EW)C(^TON4'_
M '0 /S%=DB+&@1%"JHP% P ***^4QE2<ZKYFV?186$8TURJP^DHHKE.DQ]:\
M+Z1X@3&H6BO(!A9E^5U_$5Y#XK\+V6A3,MK+<,H8 "1E/\@***]W)JL^;EN[
M'C9I"-N:VIE:)I$&IW)CFDE51C[A [^X->N:!X T'2Y(;Y(II[E"'1YY,[3Z
M@# _2BBNK-ZLXII-I&&6PBY7:.O%+117S!] %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140317705948992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000805928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AXOGEN, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">MN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-1301878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">13631 Progress Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alachua<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">32615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(386)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">462-6800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AXGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ME[1Q*%LD:2?H4#)3<ETHW<H\YENF(HRW]GV*VC;.N]C)1EY<<IX+J-^NYV&
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M=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( +* "5DD'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "R@ E999!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ LH )6428L?3O    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ LH )69E<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " "R@ E905^H@5L$   B$0  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ LH )69^@&_"Q
M @  X@P   T              ( !GPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " "R@ E9EXJ[',     3 @  "P              @ %[#P  7W)E;',O
M+G)E;'-02P$"% ,4    " "R@ E9'#AEZC\!   \ @  #P
M@ %D$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ LH )620>FZ*M
M^ $  !H              ( !T!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ LH )6660>9(9 0  SP,  !,              ( !
MM1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d831362d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>axgn-20240808.xsd</File>
    <File>axgn-20240808_lab.xml</File>
    <File>axgn-20240808_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d831362d8k.htm">d831362d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d831362d8k.htm": {
   "nsprefix": "axgn",
   "nsuri": "http://www.axogeninc.com/20240808",
   "dts": {
    "schema": {
     "local": [
      "axgn-20240808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "axgn-20240808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "axgn-20240808_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d831362d8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-08-08_to_2024-08-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d831362d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-08-08_to_2024-08-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d831362d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.axogeninc.com//20240808/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-24-197821-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-197821-xbrl.zip
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MNW&KVZYBW1RS[4%>W?0'OKUJ%P[]_!]02P,$%     @ LH )6=Z>;^-Z!@
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M/.2S]5+><:VV]*]<R7?1[!>/J#W_ U!+ P04    " "R@ E92N=B/\($  !
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M<'!0,T_CH4LCDP6:]7JKAH^'5+%X.+T=^[GA]%:,F<]]I^J(*0+?KN_7]Q-
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M[;, &EQ.A/_DZ+C=A*!OKUG9VU_6UL6EMU?P"=-\YT\_[#<;[PX5,*K' D0
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MP.N1&W"_=S5(O:O"DRU%Q=:R4;534SZ[D[F>XPCE@[/ ES3TR"?TM&$^9?/
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M'VR.P@BXZKFAI4>H+^!0YDOL=0Y6ZOEPE1<N:@NR/Y$23$6F:_]XV;NTW#/
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M.3Y?X4ZA6ZR2>C]*$R&3:?4TAVTDR@2Q!A(QD_X.B-!0.\K2HQXNHNHXYS
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MG;J+2^H9@>#-##9$PJA.- 4M$H]@K !(Q>IW&".1.DUZC9)0B1)+9<=E1-;
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M^-U;":7L4?6H%&8@94\Z5^9:4CSD)>MKEID@1JDAC;\N;2-"]MD!I8\\T=H
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M9A$R,W'S9R"!29L3J'K":Y *>WAQ$E.G5!M&?; 5;O?:F^_SVI^0#A5+5?=
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M0:8ER B6#!O9N8P9LGD>H_^N@U^69MZP5+MYIF;\+$399.S@8 <I#N%R#8(
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MCNK/):H?Y?&%2U[#Y%F8_PD"L(AC<^.?[F3\U9"ML'F=697:3@+*RZKK-^.
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M?<AV?7"%7I6C#F8S#HI$K7VR;D4^4?K)5AI83=E)$DPK.C<LEUAEC59HK+K
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M!,MUBZ 2Z_'(A1,QJXX")T$).Q@K8(WKV"A7LJ/HE4HE"3Y2\!*X.2A]E .
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MK+K-8SP_UO'WH.$*@;O8JA7O%*!CV/LB&65NJ\]H2C26M#3Q7JK"=2-)!^!
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MO< K]3.V#W9R)7:^<8"GW_C^-R_ _9[R(OQ6V2-9DC027>](WG0F1WDE<+I
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MRFK*LEF%2/@M,_RF\/5!69@?FAL\7<T-8%,/W_\#?OGQ]/=/;_Y_4$L#!!0
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M!T'J>0D3#_H44HBF34F&,N4-#J,ZK;.$@5E 4>CW3BFZ 7-EFC+V,J$ALZ6
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M</M%"/;<DCCAO>=)>88,%&'[Y 45'9W(38!E5*B)G(Z>VS#GTP"BP:=AM(+
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M#$4 [SH8=^ \!O$:3C;&J"Z=:,!'JA[@)5.VB5VV2-43$PC(M#8UYM4<,?=
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M1"EJ+O9=>F#KJ)@L-1#Z)]!V-6&N$WH%;)U9(.4V.,J%';@0$@9&JB03HSN
M_^&/X*Y,FRRXKD8Y;$45#8L"JP+=DZ$VP+\%'B6+ITQ:YC#JHQ7D%:*V2*H&
M>A@I#[S?]#E=URJMK4NDI?RB9@FR;,3]U#41H).)3H')7I;;2110)J&FEDL/
M@*__Q37CQL)57&/Z8&=1!GH?+*6.2L)TTN7A>;M$4\BYI$B7<0/9PE;B-;B@
M=FOULL73V:^"NRI37)6L<@?*Z\,^\7J.,SJGLB&5MW;"7G]2)M;G4Y3FUV/]
M-2XZ+/PJ)\X.*'/\G6:U7Q$;UUD=10?;S6;LM$T9:&Y2SA0>U"#S =A>8L-7
M</G"*4=&XXQXRI6"Q^0 KIU[1S"Q5_HIJMEC\23H[\UYP;1*JV;A*F+700Z5
M @'1V7Z,:_HM\L61\I$HNWRLB.L&NU=K&%O>/!2N7Z)K+U<'A4?^L_GZ+(3+
MX#Z628?==Y&ZE2O_UN/A\@Y"MG!2!"_*R!:M<JLEEZ]6?+$#)5DZ/T1O\61!
MXH'U#E(HZ5_U7:CUCP+/)O5'\H7KM6&2AT)@'D:3.WY/;@E8V!G00MYUPK?/
M$W:;GTR9GAC?-''?(J2+!+CK?PA;S[\@&J2LQ05:3BZ]7O%E.E5/EQTL,SL3
MI\@7-Q_;6@H<6)DDBZ)*:QWX8TXT@3&Z!!>:@LH-#]2@^J$1NXA3A!--)G!5
M*I]7(>R)JAW*EYQOH:Z3D,;$.<E<;/526H3)23NMM[>P1V/)>VA[-DEQPHNL
M0@ = B<)(G"DK0)^L+HZ@NZ]Q)IPSD,U<3BIE%,3$!,F;;G(/Q%/SI'O2C%/
M2=RF3$I)19UP"0[,/BH6I#/@WP8-:*JNR!B,()DG:*BDU=P(]O@<SLLBA:BJ
MKS'B+BU[>:5$R4DRAD.U"0SXDTDQ;MB@TK"VW@?"DT52(VEC,%K:1;D\2,(S
MD6+BY)=T-Y.X>,]@4<]8LE@C5,U(F@#,7F4WXW 837.X"\9D2\L>$L_W[$2]
M"V$SD;HX8P^*"5(*"EAK^HL0C;R(ZA&>AEYH*"31;ELX03-[0U]5;7+L,?Y,
M9:9[!WGSK+H*'XBRFJ+S3'^0(EQ#?^'=?3W,-W#DNM*T77_LZOYVG848=DR]
MPMC;XE@R!TBP9(#D)-V!MFRKC^W!\B:KJ,(QA#E':SEGSQ8XZ0'';@Q"7.)S
MK*?NT=W8H!<^<.CNCR]=>EOGU5)>@E P KAS$7[Z#;M_.&P!7X @2AG)UXG(
MN /K1:.N!:+VN_!C1VYZ_T&GI)++Q 8(+S\-;H,-3'^3CJ"?OCN";O<BVA(4
MG=[3T0=7A.[OD'9E>LD0E@#EYVI855A CZH<CAWX ?Z/_X>I>/>GS=$6,X)N
MU2<.^OJ<-)/ND?9V3Y?T((.7( W+YJ[8>BS#=C4]!Z;P+)M+.6G)L,X+I5V1
MJ9)1&3!6-SO9KL9U?F(KVZ==Q575S!?=?(G14IW6H5^\UDXT% !I@]XIDE]_
M#II^)SKA\D%M"9C:6;4K$J+#C ]*9Q^V8 ?UB7/#\6ZR8CN3?EQJU21QF1-\
M.5B^LX0L-YXR1J'=MD/9/E<%TEAE'\FL[9]PUYE"^X8TAM&>H8O2G[.]E:MR
M!B(\NW2*!,3PV)5)<Z3I@@Z-*%:J)L$=?4(.H U';$[>N$#+9^(T)J)46[[O
MTK.0BG>KKK58_NS4O<T;%P47#A;=SG6KKG3U.MDF-[EY7Y_N;&8*Y_U^<'7"
M]MBAU9-IZY+S/IM/AW1:QW\E&*9T_B]-1PZZD*P7*D^) _2I[70N=Z!UV_1K
M C:>4&2FBO8SA"]Y_7MCL**K1=?6(*A)B*4$*V:^X&*$# V8+Y1[]X4L+\%;
MRNMM[!,_.SH^B<X::2 $UW#>9&=LJ[NYM=.P]*@X^8H_#/_R<^BOQW3D:[4F
MPJ];)JSQ/&A9.7@4Q$W'NK"6!'GVJ]HQK<Z6P+$$M?."J)?9X!8D''^JC?"X
MM(0 H$^(#Z-!<RBES 7]O-D# /<TWQD<]+/-!UN;K[8VTRU[;%NK>A3YQ'$M
M*,<LO.^]\)O3D@JEN&(Y5%7J\NKVP3QW=W"FV[N;LZTM+1+/ON5V6-_$"8UM
MYU$LBN/R:%?3.F[5R@0D&)2$K=)/T>:3L!=;[<NPD2ZCEB=Y:'/63@HI9 BG
M[6MHXB0VI58QEYWN5#(D6LM N&"YM,A.7B'1?3,BKW'.)9!,Z8S+URP5_J8R
M LPV%=5UDF24M=O9>AJ-MSX-JP$!&R8O!JMPY.)59(6KCD9U4?CC7*ORM.*T
M,C@SK>[]DF:H:#/C]L$6:UC5$L0Y%7]/JX#C!= /J1RED1W))9;+1=G%IBE+
ME_/AABG-(Z2X1?37)/D'H,7!]93%O2Y*I?ZUDQB*R\ UG725&WQF;7_\P\?Q
MG9(<P(J=0JU,G2LG,+J5"GC+6WW]L-YWN]%KJK(R43JD6LU:=W#5V$H0IK\E
MU7#_^N(X!*5O#-X'Y6]^PU0J1!I*?4#7L??4R)A9C-D,8#VP A<6T)GK"+0=
MF(-JE&I3.*?'&^V#.L*&$ +ABUXIQ%J=7*L&Q\H]HG]UE6)4,^BMQL^-,DH#
MR!/0K/T-0T/.5U7$%A7<MX(O_]#DKDH,E\$B- K66.8:JFH$="8<;@,N'Z:
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MC35SG,EN)D#MIF,GLR]R8_# UL[LLY69;6NRK99;UYRMF>30M Z1+G=IU3V
MN*,4<9T[AO3X'TMF2E_JA%=:4SD&>RY&S[=;>,;%$2@C3YM6R"7FXOS])8KM
MNR2C5WA(V%*+#B2@/LEZO\(&5%P?<I2XAJ]+?PI>VU 70;!:14_CYUQELPQ.
M$!T@[B9[)\.Z(7I2%?T#?X/+ON\E0[<FGL]BTBS>V"-+J!J3JXJ^$-7=^C9H
MI):S44H+A@OO\6_<H;FS>:![T@,XQ((MO?+=5XP,A.##W:>;<5 .C=/$N2Z.
MTUZ-6X<NR(YV4_.%B6+%/14+->/-=7 .(4(U.<&-K@"22*)Z!R-L:BY!U7E7
M[I!5_G4;@Y:;[&KO; VTQ59#&\?95X35H3&H!F=G]<FGI!RG%3=2*Z0S863[
M.B,@JHX)"I,M=0#VOTU5/?C,JG*@+#WYZ?GNSM.'VP^I7K#K&1-M_KFU->S?
M5V)U"^N%,?ZRJVTG__PN8E935XV3(^X_4<1=L9^3;D ^PD^\W7>$/!_]M,<)
MI[1S9W)4^)X^N2Q2Z7*<362=*YCS5O<<HV3': &3B<N:ESX"7G,'X]N5C_0Q
MZ-XYG_BTM."U!UAUK.;,S6.7&*II/%QA<>PXH64')A&=VJ4@!$VX+>H "%8.
MJUWJ5(<6&!B"#BJ/F.W_[5W0S]E:^I',I'6H#HU?.B!])[.=G)-WL;;9)6O3
MXE;K[H@OAR4XC4[X TA,_"+_[?[._5T4NOPK<S^<'#6PBMPUGG.*N/1H36Y>
M>O;ZFY6NV2QU8O<;I>*6OO/C_G/-"EZCZ^LW=GW]CH?5MQ2)G+D#Y*B9!-\I
M/84J)DDM=Y_UTBE60:G&? GNP+'@XKBI2G%M-22^/ZU.'11XVPR;7G2K;DR[
MOX'-X3Z47(Y^(E6@43Z4L?IHO5<4O<G=IJ=;G*6J.'5[1^S#Z&:HL*]86LVH
MH*1[BH=AB4,ME- S,,X*\NK#XL>).=*B5==.]X)YLG./"J8I4BN8G<QYN)_4
MN;O=PK58V;XS)6:9^RV+>G>,5:N\X/P0CD@5R!1DKC*;H4Z'.F%Y30UKP;HY
MQ#S(1>Q'X=Q]\X$+GE0%6%6) MI;9>$I:O3\F_7'[C[X[HW],L';:S$9T:_7
MWW;I$W[9=1\U=>\+_M44M090W6OP0U9/N,^NH!8P._3,*2JS]&R&[H^1M&3*
MP-1!['WU%Q7.I)9QO<L*N(2]6B1/5D["W'4>'7AHF=SDOLLD+Q(SS,TN/$SA
MZR,#QBWBZM"01/DOX:3Y;8@5-+#+ZQ 5ZX)7+V#E$H PM9;L9BE9YW.5S'<X
M.G\S3^I9,5&<-/_%N2J4DX:E;^&N#9W=4L=_<2X&)T%@D@ZA01:+,@:#W04A
M,4J(.8EAE+)S#%@?KQEW-H427,?%60Y'/3&#3]-R+D35LR5?/[>UIR'1QL#=
MJB'=/>GZ/FQUA!?>,*9<G#%F^6'.'-^N3L8<^4!\BT7_7?O2H:%9M;HXPP,=
MQ?7*-=+:U16;/*5"V]02,L?JAN@2I&1R; 1..T'=2.))L9!#2NN_!9STKSXX
MJ6](LQ)@[ &T"A*(-P9!X6"NGJG%L%O=0_A:!@T.[V#Q6=_B>38K%TYTRECS
M+*EKBH]IQJUM,^R21VWW5*EL9(')V,<<29NWIG99#L2=5F[H71B!\[[=@HF%
M6R7UT ('ALE(&],]TC(!W#6>ZH;WFA"(E=$*!2RIPWK!06V_Y!:KB5U_=_*^
MW?EW[C /AW_L*E:LI*Q6_0G*KE/W&V7P@ Y38YQ7<W-1OZK23_4RVGQR7[!F
MW!J\QOJ86$P+\9>[^MTRB4N-[&/SI:*I] 5#0Z98&,F@P-&"_!T>V?Z =3XF
M G6+1\5YXMJKD/ A+N9J#P?3-Q7@315Y\TI_'UH+N$BR<Q ?F[L/@DI[3$[:
MF%?[>NNNF?(@S)T"04%)!82D#7[,J;$]G'^6)M/HUP:..<+BGJC85=%[:BC<
MKJL>E#RZ;./LJE5Z=[80F]K(";F,""62M'(8H'V&Y(9=O0T>K)YAS:O-AP$E
M!.U7\2./B.V\RQ1$T<Y1[AP-_L T\YFEF#B+!=[01^"ZNI4)YN#>0E&QZU_1
MHG-%94F=Z]BJVS-T)6SB*U7] A5@V_6>UE#)1#Q]1E[HJ)SP!EN'H>).O1DM
MR> R 4T?@-*4J>D#+=#Y4)&;R54&!K(<AJWC*7.0?1V^O(>O:M-7/6.HX?-)
MX@M[,"164#4T$R8TK4\G.)=)D(&F.,'>?1*#5WW%1_EXASN2UY6)#+ =XE9H
MO<OXB\X/[H(N%WVB PZW)2E@JJT'^KW&M:U H Q*F^^6R518C=B\6L0[<[EP
M0EW_G"4YAB/IJ0O0=^7M<&+M">%UD<]2J;(O">R^1V#1:>HL.9II.6[FJ"*3
M>8T1+/%ZZ"^K&;6BRHHSJ19I6^L,H_7.5:JKPN U+>Y(&MS050; @)/O:GW.
M" 9&6XU3J9%P,9/"3J*'+1GZ[RMOC"0C '^Z%%\"UT)'>(#F8'*E[5'C;PGN
M:]796)_':G;VDKB9K.=N\NL/N="7.]MO.Z=^]^%WC^8M;B>R*],;-J)&D1@3
M_,J$"O,X56O!]ID]]M4JV.KX2+5-[FB*=F:_2Q$[G<HU#9IK22$^)?-VRJO"
MG #D1GN9UC/"W3N%=X$U_Z[1X"2Q17NN_3-]<AL31;1RMTVPA(!$T=W'9FD3
M4&C_0*U64X:P]@<A=U\GH[)!UO[@@>;ZYIK[L#'0;YGUR",_K34IG][>">QK
MT47>ZCVN! L;;*CATOMS*QM-H7PR%/%FB IV.BN+YFS6=P*LC'S1LS^:<A(W
M&'<Q8=%[3%DD 9HB"7L63'4OS6A^)>UP'A*S:WFXOCNU5[OEV+QBM9^4Q@MT
M0-[-^O))^5:6E/_RK"//_88]\2)TI40-)"@,<[KWZNVA#O7J_?'!X?$VB)JW
M>Q].#I_I/]:>0OO([D4\S"_W[M^+]@_?OOVP=W!P].Z-^_ODP]Z^_FW%&,_G
MF 5>]$MTS\C)E(R89]3]4AX\T!\_^L$OZO2@]>5C$(^_"U>%37$<EL7>YJ<M
M^QO[7? K2\-1N,713:GX>=2:%.&J^CCJ\PBNX!S;.". $I5,IU;1*N"_CO&_
M\$B_D\AMD<CR;T@B'^(E>GD^N SIG2M0P:VK""1YVS-Q'- :8>1O*((*'.H
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MYOIV:UM< J4&#?7]P1_PX:^GO[U]^?\ 4$L#!!0    ( +* "5GS-K=I"D$
M )HH 0 1    9#@S,3,V,F1E>#$P,RYH=&WM?>MSVTB2YW=&\'] >*XWI A(
M;?G5;MOC"-F2W=ISVUY)[MFY;R  DFB#  </R=R+_=\O7U65!8"49,E2^]83
M,3,6"1;JD97/7V:^^.WT]W<O7_QVN'_P<CQZ<7IT^N[PY>%_[NS=WWWXXF?^
M$S[_61X(7KSZ</#/X-7;UQ_>?3C^^[U__'9T>G@O.#G]Y[O#O]_+LR+=F:?9
M;-X\>U]6BRB_]S(8C^#WK].B2:N7+PZ._C /GV=),W_V=/=Q5MP+HCR;%3!
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M:E0YT 8=4 K6W88 _>K+-9ZIWMD$^G">=F[$-W?/&W_GSMY.('<0?4\'1W_
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M/)*[A![J\0A(&GA8D]O4*[C,Z#A!>H,Y-BLA,\X[<TMR="PKP8MAIN]=/)1
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MP2HE9BC6IN9V+%]% W0TCANN;C(PCI]UT,IEL;#9FJ!UUL"ZK>5'::51/;=
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M83R*VP4Z;M ;S\%EKD3)C8.$9M 08P8#(Z*.$6@<_2J09D&8&!,CYA_-$S>
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MJ0XJ&:0QU\9ID:=2?>HXRN-6:MU(5PZ:M9'ME+]G5B3?<?.->HD8\H$0?+=
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M 6YN:D>;],H?R>WF/FF:A5?ZS]IY-,8CZ])8]WJG<7NA]>X\K+4_]-0DQ<-
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MR0>X-_\&([A5^ERDLB20_%0"<LQ-E2S9/Y*'A6C?H1#%)/'TJ4FU8?FM 9U
MIC! R,B2]@\2N%NY=J7PP;J\0B0D0> 2;^]VT,BE53UQ78L>LAN-=/A6\B,J
MF)E*YH&<!79!+%#18)2="3Y;1<MQ-0-4?69)8[VZH'J[H^=9+6CNSP'0[XXQ
MJI\\5D8$,*0XM')Q11<OC' H!C.R_C+UP5E:%:7?6M""!P(V,RV!_$5E7>5[
MEP:@G5+<?E@DF9KZ H\XB+7W9B0Y+K%"ANB.%6$K)2-"^H'#M(X0"L22'LIY
M,:2KHJ0MBH]3U4)V2O(E$YH;A%>-=?3SUM#$HXCBN9\(HT4K:3*2+?I-^JT\
M##H5+A:;0$:?5S,V"F,:!/N+!1FF6)_(F*4F?>H)^*).NFZG-HQ/<S]50NW/
M ?'4TO6WN4Z4BR)4*R0[DH@MWT"^QW1&.E_IF)&&J_2P741WZ2;K^R(;$ %M
MA[\I)3>0B92F20'J UU@H,P3\[!U<RJ!4G.J0JYEU"7(IEZ@11@#<[LH4+FI
MAD]1_-MYSUYSZ#"46QLV/* A3/VU/QT9QVPC'!1KME =C.&>G2:&VR'U&UR(
M_1:8KQW^NW"^+Y9@[8G_'Z#MK9:!WDJI6PT?5>'MC3\^<373Z0YB8L>!&D[7
MQJWUO!<\JJ*!B[<,!# SDLK3(ZOCF4]V*$3@M,&M*!QK?@0C&CO1,0^ED%_.
M\!UZF*5)[$+XU"J%D-B_L5/1D()M0ET8$Q-C?[]YR:3P842OJ;AJDE61<5*H
MCW1MC=2G&TF:"EC]43P>G5T^@>2R* /OUC'K7BH>M?"M?X@7IC:?,,2Z'N+&
MFG*I1K?S!16!R'54>O)!PR@XO)[CT+F!'6YSF>\L@)[8N'YW; O\(J!H6L33
M)>ZH'6J1*+5S=$E7ENC3^96-EN9OAW_YX]I_MW?P[%^J3Y,OD<H%OYS1CC%B
MN,#ADJX[DH5,41RH1<(),\V]THR&<U02/Y8[K7:K=;<=*^+_WJPJ3[B?]A::
MI;[V!3MS4^$2@,5.&!#FLQW@=U8[@1NMS[XI!N,](-G_(N[(N/?>N)<^-/_-
M^+^_7!HM W?7.]X^,LNU(5Y)-PDH >TDKZ.G#AK?!!72\A4Q2]/<Z#=I.\&:
MUMBA&<H6"3F%6A=>2'>ME#;'O.M:=IS)XDNG][:L:/3:](#*XS5UFT3@@AY4
MMC0?YFJ</VC$4GT- !"H0O:LOJK4[;A%5J"(,9?GV^(5HL+4N^[HMS<4=.GP
M('7*X]I@_9]SOKJ]*R6_,W$F<QG+?ONGGR!E3*3B#GB<B)]0SV4_J/C BAOF
M$Z.*FD#I)PS,-_+ZO19^S\E^FU<C7O,5.5] A?=,J'6ANXM2S.?S7<D60LG=
M15GY^OSAY-4I"@] K3RB'NASXZ<OTC*LO*?ZE<]Z*T'A8G&.T$-16)B^^(6&
MIS>@/D"P$+6O 8^$='P_DS_P $G<JK35''Y%$9.2)?N?%:]_IB.%AZ[/?\67
M_']P^S]02P$"% ,4    " "R@ E9 7>?_3\#  !."P  $0
M@ $     87AG;BTR,#(T,#@P."YX<V102P$"% ,4    " "R@ E9WIYOXWH&
M  "X1@  %0              @ %N P  87AG;BTR,#(T,#@P.%]L86(N>&UL
M4$L! A0#%     @ LH )64KG8C_"!   0"P  !4              ( !&PH
M &%X9VXM,C R-# X,#A?<')E+GAM;%!+ 0(4 Q0    ( +* "5DNJ7BY$!@
M !R,   .              "  1 /  !D.#,Q,S8R9#AK+FAT;5!+ 0(4 Q0
M   ( +* "5DZUVBN'V4  ) 4 @ 1              "  4PG  !D.#,Q,S8R
M9&5X,3 Q+FAT;5!+ 0(4 Q0    ( +* "5F,DA].-$(   @N 0 1
M      "  9J,  !D.#,Q,S8R9&5X,3 R+FAT;5!+ 0(4 Q0    ( +* "5GS
M-K=I"D$  )HH 0 1              "  ?W.  !D.#,Q,S8R9&5X,3 S+FAT
M;5!+ 0(4 Q0    ( +* "5E<>&KX(Q$  .<V   1              "  380
I 0!D.#,Q,S8R9&5X.3DQ+FAT;5!+!08     "  ( /T!  "((0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d831362d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="axgn-20240808.xsd" xlink:type="simple"/>
    <context id="duration_2024-08-08_to_2024-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-319">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-08-08_to_2024-08-08"
      id="Hidden_dei_EntityCentralIndexKey">0000805928</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-330">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-331">2024-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-332">AXOGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-333">MN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-334">001-36046</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-335">41-1301878</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-336">13631 Progress Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-337">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-338">Alachua</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-339">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-340">32615</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-341">(386)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-342">462-6800</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-343">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-344">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-345">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-346">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-347">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-348">AXGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-349">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-08-08_to_2024-08-08" id="ixv-350">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
